Document:

REGISTRATION
RIGHTS AGREEMENT

REGISTRATION
RIGHTS AGREEMENT (this “Agreement”), dated as of July 14, 2020 (the “Execution Date”),
is entered into by and between NUGENEREX IMMUNO-ONCOLOGY INC., a Delaware corporation (the “Company”),
and OASIS CAPITAL, LLC, a Puerto Rico limited liability company (together with its permitted assigns, the “Buyer”).
Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in that certain Equity
Purchase Agreement by and between the parties hereto, dated as of the Execution Date (as amended, restated, supplemented or otherwise
modified from time to time, the “Purchase Agreement”).

WHEREAS:

The
Company has agreed, upon the terms and subject to the conditions of the Purchase Agreement, to sell to the Buyer up to Fifty Million
Dollars ($50,000,000.00) of Put Shares, and to induce the Buyer to enter into the Purchase Agreement, the Company has agreed to
provide certain registration rights under the Securities Act of 1933, as amended, and the rules and regulations thereunder, or
any similar successor statute (collectively, the “Securities Act”), and applicable state securities laws.

NOW,
THEREFORE, in consideration of the promises and the mutual covenants contained herein and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Company and the Buyer hereby agree as follows:

 1. DEFINITIONS.

 

As
used in this Agreement, the following terms shall have the following meanings:

a.                  
“Investor” means the Buyer, any transferee or assignee thereof to whom the Buyer assigns its rights under this
Agreement in accordance with Section 9 and who agrees to become bound by the provisions of this Agreement, and any transferee
or assignee thereof to whom a transferee or assignee assigns its rights under this Agreement in accordance with Section 9
and who agrees to become bound by the provisions of this Agreement.

b.                 
“Person” means any individual or entity including but not limited to any corporation, a limited liability company,
an association, a partnership, an organization, a business, an individual, a governmental or political subdivision thereof or
a governmental agency.

c.                  
“Register,” “Registered,” and “Registration” refer to a registration
effected by preparing and filing one or more registration statements of the Company in compliance with the Securities Act and/or
pursuant to Rule 415 under the Securities Act or any successor rule providing for the offering of securities on a continuous basis
(“Rule 415”), and the declaration or ordering of effectiveness of such registration statement(s) by the United
States Securities and Exchange Commission (the “SEC”).

d.                 
“Registrable Securities” means all of the (i) Commitment Shares, (ii) Put Shares which have been, or which
may, from time to time be issued, including without limitation all of the shares of Common Stock which have been issued or will
be issued to the Investor under the Purchase Agreement (without regard to any limitation or restriction on purchases), (iii) any
and all shares of capital stock issued or issuable with respect to each of the Transaction Documents, and (iv) any and all shares
of capital stock issued or issuable with respect to the Put Shares, Commitment Shares and the Purchase Agreement as a result of
any stock split, stock dividend, recapitalization, exchange or similar event or otherwise, without regard to any limitation on
purchases under the Purchase Agreement.

e.                  
“Registration Statement” means one or more registration statements of the Company on Form S-1 covering the
resale of the Registrable Securities including the Initial Registration Statement and any New Registration Statement or Other
Registration Statement (each as defined herein).

 2. REGISTRATION.

 

a.                  
Mandatory Registration. The Company shall, by July 31, 2020, file with the SEC an initial Registration Statement on Form
S-1 covering the maximum number of Registrable Securities as shall be permitted to be included thereon in accordance with applicable
SEC rules, regulations and interpretations so as to permit the resale of such Registrable Securities by the Investor, including
but not limited to under Rule 415 under the Securities Act at then prevailing market prices (and not fixed prices) (the “Initial
Registration Statement”). The Initial Registration Statement shall register only Registrable Securities. The Company
shall use its commercially reasonable efforts to have the Initial Registration Statement and any amendment thereto declared effective
by the SEC at the earliest possible date.

b.                 
Rule 424 Prospectus. In addition to the Initial Registration Statement, the Company shall, as required by applicable securities
regulations, from time to time file with the SEC, pursuant to Rule 424 promulgated under the Securities Act, such prospectuses
and prospectus supplements, if any, to be used in connection with sales of the Registrable Securities under each Registration
Statement. The Investor and its counsel shall have a reasonable opportunity to review and comment upon such prospectuses prior
to its filing with the SEC, and the Company shall give due consideration to all such comments. The Investor shall use its commercially
reasonable efforts to comment upon any prospectus within two (2) business days from the date the Investor receives the final pre-filing
version of such prospectus.

c.                  
Sufficient Number of Shares Registered. In the event the number of shares available under the Initial Registration Statement
is insufficient to cover all of the Registrable Securities, the Company shall amend the Initial Registration Statement or file
a new Registration Statement (a “New Registration Statement”), so as to cover all of such Registrable Securities
(subject to the limitations set forth in Section 2(e)) as soon as practicable, but in any event not later than ten (10)
business days after the necessity therefor arises, subject to any limits that may be imposed by the SEC pursuant to Rule 415 under
the Securities Act. The Company shall use its commercially reasonable efforts to cause such amendment and/or New Registration
Statement to become effective as soon as practicable following the filing thereof. In the event that any of the Registrable Securities
are not included in the Initial Registration Statement, or have not been included in any New Registration Statement, and the Company
files any other registration statement under the Securities Act (other than on Form S-4, Form S-8, or with respect to other employee
related plans or rights offerings) (an “Other Registration Statement”), then the Company shall include in such
Other Registration Statement first all of such Registrable Securities that have not been previously Registered, and second any
other securities the Company wishes to include in such Other Registration Statement. The Company agrees that it shall not file
any such Other Registration Statement unless all of the Registrable Securities have been included in such Other Registration Statement
or otherwise have been Registered for resale as described above.

d.                 
Effectiveness. The Investor and its counsel shall have a reasonable opportunity to review and comment upon any Registration
Statement and any amendment or supplement to such Registration Statement and any related prospectus prior to its filing with the
SEC, and the Company shall give due consideration to all reasonable comments. The Investor shall furnish all information reasonably
requested by the Company for inclusion therein. The Company shall use commercially reasonable efforts to keep all Registration
Statements effective, including but not limited to pursuant to Rule 415 promulgated under the Securities Act and available for
the resale by the Investor of all of the Registrable Securities covered thereby at all times until the earlier of (i) the date
as of which the Investor may sell all of the Registrable Securities without restriction pursuant to Rule 144 promulgated under
the Securities Act without any restrictions (including any restrictions under Rule 144(c) or Rule 144(i)) and (ii) the date on
which the Investor shall have sold all the Registrable Securities covered thereby and no Put Shares remain issuable under the
Purchase Agreement (the “Registration Period”). In the event that any Registration Statement filed hereunder
is no longer effective and Rule 144 is available for sales of the Registrable Securities, the Company shall provide an opinion
upon request of the Investor that the Investor may sell any such Registrable Securities held by the Investor pursuant to Rule
144 with all costs related to such opinion to be borne by the Company. Each Registration Statement (including any amendments or
supplements thereto and prospectuses contained therein) shall not contain any untrue statement of a material fact or omit to state
a material fact required to be stated therein, or necessary to make the statements therein, in light of the circumstances in which
they were made, not misleading.

e.                  
Offering. If the staff of the SEC (the “Staff”) or the SEC seeks to characterize any offering pursuant
to a Registration Statement filed pursuant to this Agreement as constituting an offering of securities that does not permit such
Registration Statement to become or remain effective and be used for resales by the Investor under Rule 415 at then-prevailing
market prices (and not fixed prices) by comment letter or otherwise, or if after the filing of the Initial Registration Statement
with the SEC pursuant to Section 2(a), the Company is otherwise required by the Staff or the SEC to reduce the number of
Registrable Securities included in such initial Registration Statement, then the Company shall reduce the number of Registrable
Securities to be included in such Initial Registration Statement (with the prior consent, which shall not be unreasonably withheld,
of the Investor and its legal counsel as to the specific Registrable Securities to be removed therefrom) until such time as the
Staff and the SEC shall so permit such Registration Statement to become effective and be used as aforesaid. In the event of any
reduction in Registrable Securities pursuant to this paragraph, the Company shall file one or more New Registration Statements
in accordance with Section 2(c) until such time as all Registrable Securities have been included in Registration Statements
that have been declared effective and the prospectus contained therein is available for use by the Investor. Notwithstanding any
provision herein or in the Purchase Agreement to the contrary, the Company’s obligations to register Registrable Securities
(and any related conditions to the Investor’s obligations) shall be qualified as necessary to comport with any requirement
of the SEC or the Staff as addressed in this Section 2(e).

 3. RELATED OBLIGATIONS.

 

With
respect to a Registration Statement and whenever any Registrable Securities are to be Registered pursuant to Section 2,
including on any Other Registration Statement, the Company shall use its commercially reasonable efforts to effect the registration
of the Registrable Securities in accordance with the intended method of disposition thereof and, pursuant thereto, the Company
shall have the following obligations:

a.                  
The Company shall prepare and file with the SEC such amendments (including post-effective amendments on Form S-1) and supplements
to any Registration Statement and any Other Registration Statement and the prospectus used in connection with such Registration
Statement and Other Registration Statement, which prospectus is to be filed pursuant to Rule 424 promulgated under the Securities
Act, as may be necessary to keep the Registration Statement effective at all times during the Registration Period, and, during
such period, comply with the provisions of the Securities Act with respect to the disposition of all Registrable Securities of
the Company covered by the Registration Statement or applicable Other Registration Statement until such time as all of such Registrable
Securities shall have been disposed of in accordance with the intended methods of disposition by the seller or sellers thereof
as set forth in such registration statement.

b.                 
The Company shall permit the Investor to review and comment upon each Registration Statement or any Other Registration Statement
and all amendments and supplements thereto at least two (2) business days prior to their filing with the SEC, and not file any
document in a form to which Investor reasonably objects. The Investor shall use its commercially reasonable efforts to comment
upon the Registration Statement or any Other Registration Statement and any amendments or supplements thereto within two (2) business
days from the date the Investor receives the final version thereof. The Company shall furnish to the Investor, without charge,
and within one (1) business day, any comments and/or any other correspondence from the SEC or the Staff to the Company or its
representatives relating to the Registration Statement or any Other Registration Statement. The Company shall respond to the SEC
or the Staff, as applicable, regarding the resolution of any such comments and/or correspondence as promptly as practicable and
in any event within two weeks upon receipt thereof.

c.                  
Upon request of the Investor, the Company shall furnish to the Investor, (i) promptly after the same is prepared and filed with
the SEC, at least one copy of such Registration Statement and any amendment(s) thereto, including financial statements and schedules,
all documents incorporated therein by reference and all exhibits, (ii) upon the effectiveness of any Registration Statement, a
copy of the prospectus included in such Registration Statement and all amendments and supplements thereto (or such other number
of copies as the Investor may reasonably request) and (iii) such other documents, including copies of any preliminary or final
prospectus, as the Investor may reasonably request from time to time in order to facilitate the disposition of the Registrable
Securities owned by the Investor. For the avoidance of doubt, any filing available to the Investor via the SEC’s live EDGAR
system shall be deemed “furnished to the Investor” hereunder.

d.                 
As promptly as practicable after becoming aware of such event or facts, the Company shall notify the Investor in writing of the
happening of any event or existence of such facts as a result of which the prospectus included in any Registration Statement,
as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein
or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, and promptly
prepare a supplement or amendment to such Registration Statement to correct such untrue statement or omission, and deliver a copy
of such supplement or amendment to the Investor (or such other number of copies as the Investor may reasonably request). The Company
shall also promptly notify the Investor in writing (i) when a prospectus or any prospectus supplement or post-effective amendment
has been filed, and when a Registration Statement or any post-effective amendment thereto has become effective (notification of
such effectiveness shall be delivered to the Investor by email or facsimile on the same day of such effectiveness and by overnight
mail), (ii) of any request by the SEC for amendments or supplements to any Registration Statement or related prospectus or related
information, and (iii) of the Company’s reasonable determination that a post-effective amendment to a Registration Statement
would be appropriate.

e.                  
The Company shall use its commercially reasonable efforts to prevent the issuance of any stop order or other suspension of effectiveness
of any registration statement, or the suspension of the qualification of any Registrable Securities for sale in any jurisdiction
and, if such an order or suspension is issued, to obtain the withdrawal of such order or suspension at the earliest possible moment
and to notify the Investor of the issuance of such order and the resolution thereof or its receipt of actual notice of the initiation
or threat of any proceeding for such purpose. In addition, if the Company shall receive any comment letter from the SEC relating
to any Registration Statement under which Registrable Securities are Registered, the Company shall notify the Investor of the
issuance of such order and use its commercially reasonable efforts to address such comments in a manner satisfactory to the SEC.

f.                   
The Company shall (i) cause all the Registrable Securities to be listed on each securities exchange on which securities of the
same class or series issued by the Company are then listed, if any, if the listing of such Registrable Securities is then permitted
under the rules of such exchange, or (ii) secure designation and quotation of all the Registrable Securities on the Principal
Market. The Company shall pay all fees and expenses in connection with satisfying its obligation under this Section.

g.                 
The Company shall cooperate with the Investor to facilitate the timely preparation and delivery of DWAC Shares representing the
Registrable Securities to be offered pursuant to any Registration Statement. “DWAC
Shares” means shares of Common Stock that are (i) issued in electronic form, (ii) freely tradable and transferable and
without restriction on resale and (iii) timely credited by the Company to the Investor’s or its designee’s specified
DWAC account with The Depository Trust Company (“DTC”) under the DTC/FAST Program, or any similar program hereafter
adopted by DTC performing substantially the same function.

h.                 
The Company shall at all times maintain the services of its Transfer Agent and registrar with respect to its Common Stock.

i.                   
If reasonably requested by the Investor, the Company shall (i) immediately incorporate in a prospectus supplement or post-effective
amendment such information as the Investor believes should be included therein relating to the sale and distribution of Registrable
Securities, including, without limitation, information with respect to the number of Registrable Securities being sold, the purchase
price being paid therefor and any other terms of the offering of the Registrable Securities; (ii) make all required filings of
such prospectus supplement or post-effective amendment as soon as practicable upon notification of the matters to be incorporated
in such prospectus supplement or post-effective amendment; and (iii) supplement or make amendments to any Registration Statement,
if the Investor receives advice from counsel that such supplement or amendment is legally required and such advice is provided
to the Company.

j.                   
The Company shall use its commercially reasonable efforts to cause the Registrable Securities covered by any Registration Statement
to be registered with or approved by such other governmental agencies or authorities as may be necessary to consummate the disposition
of such Registrable Securities.

k.                 
Within five (5) business day after any Registration Statement which includes Registrable Securities is ordered effective by the
SEC, or any prospectus supplement or post-effective amendment including Registrable Securities is filed with the SEC, the Company
shall deliver, and shall cause legal counsel for the Company to deliver, to the Transfer Agent for such Registrable Securities
(with copies to the Investor) confirmation that such Registration Statement has been declared effective by the SEC in the form
attached hereto as Exhibit A. Thereafter, if requested by the Investor at any time, the Company shall require its counsel
to deliver to the Investor a written confirmation whether or not (i) the effectiveness of such Registration Statement has lapsed
at any time for any reason (including, without limitation, the issuance of a stop order) (ii) any comment letter has been issued
by the SEC and (iii) whether or not the Registration Statement is current and available to the Investor for sale of all of the
Registrable Securities.

l.                   
The Company shall take all other reasonable actions necessary to expedite and facilitate disposition by the Investor of Registrable
Securities pursuant to any Registration Statement.

For
purposes of clarity any reference to Other Registration Statement in this Section 3 shall only refer to an Other Registration
Statement that includes Registerable Securities.

 4. OBLIGATIONS OF THE INVESTOR.

 

a.                  
The Company shall notify the Investor in writing of the information the Company reasonably requires from the Investor in connection
with any Registration Statement hereunder. The Investor shall furnish to the Company such information regarding itself, the Registrable
Securities held by it and the intended method of disposition of the Registrable Securities held by it as shall be reasonably required
to effect the registration of such Registrable Securities and shall execute such documents in connection with such registration
as the Company may reasonably request. Notwithstanding the foregoing, the Registration Statement shall contain the “Selling
Stockholder” and “Plan of Distribution” sections, each in substantially the form provided to the Company by
the Investor.

b.                 
The Investor agrees to cooperate with the Company as reasonably requested by the Company in connection with the preparation and
filing of any Registration Statement hereunder.

c.                  
The Investor agrees that, upon receipt of any notice from the Company of the happening of any event or existence of facts of the
kind described in Section 3(f) or the first sentence of Section 3(e), the Investor will immediately discontinue
disposition of Registrable Securities pursuant to any Registration Statement(s) covering such Registrable Securities until withdrawal
of a stop order contemplated by Section 3(f) or the Investor’s receipt of the copies of the supplemented or amended
prospectus contemplated by Section 3(e). Notwithstanding anything to the contrary, the Company shall cause its Transfer
Agent to promptly issue DWAC Shares in accordance with the terms of the Purchase Agreement in connection with any sale of Registrable
Securities with respect to which an Investor has entered into a contract for sale prior to the Investor’s receipt of a notice
from the Company of the happening of any event of the kind described in Section 3(f) or the first sentence of Section
3(e) and for which the Investor has not yet settled.

 5. EXPENSES OF REGISTRATION.

 

All
reasonable expenses, other than sales or brokerage commissions, incurred in connection with registrations, filings or qualifications
pursuant to Sections 2 and 3, including, without limitation, all registration, listing and qualifications fees,
printers and accounting fees, and fees and disbursements of counsel for the Company, shall be paid by the Company.

 6. INDEMNIFICATION.

 

a.                  
To the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend the Investor, each
Person, if any, who controls or is under common control with the Investor, the members, the directors, officers, partners, employees,
agents, representatives of the Investor and each Person, if any, who is an “affiliate” of the Investor within the
meaning of the Securities Act or the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (each,
an “Indemnified Person”), against any losses, claims, damages, liabilities, judgments, fines, penalties, charges,
costs, attorneys’ fees, amounts paid in settlement or expenses, joint or several, (collectively, “Claims”)
incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken
from the foregoing by or before any court or governmental, administrative or other regulatory agency, body or the SEC, whether
pending or threatened, whether or not an Indemnified Person is or may be a party thereto (“Indemnified Damages”),
to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in
respect thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement of a material fact in a
Registration Statement, any Other Registration Statement or any post-effective amendment thereto or in any filing made in connection
with the qualification of the offering under the securities or other “blue sky” laws of any jurisdiction in which
Registrable Securities are offered (“Blue Sky Filing”), or the omission or alleged omission to state a material
fact required to be stated therein or necessary to make the statements therein not misleading, other than any information in a
Registration Statement or Other Registration Statement that was provided to the Company by the Investor, (ii) any untrue statement
or alleged untrue statement of a material fact contained in the final prospectus (as amended or supplemented, if the Company files
any amendment thereof or supplement thereto with the SEC) or the omission or alleged omission to state therein any material fact
necessary to make the statements made therein, in light of the circumstances under which the statements therein were made, not
misleading, other than any information in a the final prospectus that was provided to the Company by the Investor, (iii) any violation
or alleged violation by the Company of the Securities Act, the Exchange Act, any other law, including, without limitation, any
state securities law, or any rule or regulation thereunder relating to the offer or sale of the Registrable Securities pursuant
to a Registration Statement or any Other Registration Statement or (iv) any material violation by the Company of this Agreement
(the matters in the foregoing clauses (i) through (iv) being, collectively, “Violations”). The Company shall
reimburse each Indemnified Person promptly as such expenses are incurred and are due and payable, for any reasonable legal fees
or other reasonable expenses incurred by them in connection with investigating or defending any such Claim. Notwithstanding anything
to the contrary contained herein, the indemnification agreement contained in this Section 6(a): (i) shall not apply to
a Claim by an Indemnified Person arising out of or based upon a Violation which occurs in reliance upon and in conformity with
information about the Investor furnished in writing to the Company by such Indemnified Person expressly for use in connection
with the preparation of a Registration Statement, any Other Registration Statement or any such amendment thereof or supplement
thereto, if such prospectus was timely made available by the Company pursuant to Section 3(c) or Section 3(e); (ii)
with respect to any superseded prospectus, shall not inure to the benefit of any such person from whom the person asserting any
such Claim purchased the Registrable Securities that are the subject thereof (or to the benefit of any person controlling such
person) if the untrue statement or omission of material fact contained in the superseded prospectus was corrected in the revised
prospectus, as then amended or supplemented, if such revised prospectus was timely made available by the Company pursuant to Section
3(c) or Section 3(e), and the Indemnified Person was promptly advised in writing not to use the incorrect prospectus
prior to the use giving rise to a violation and such Indemnified Person, notwithstanding such advice, used it; (iii) shall not
be available to the extent such Claim is based on a failure of the Investor to deliver or to cause to be delivered the prospectus
made available by the Company, if such prospectus was timely made available by the Company pursuant to Section 3(c) or
Section 3(e); and (iv) shall not apply to amounts paid in settlement of any Claim if such settlement is effected without
the prior written consent of the Company, which consent shall not be unreasonably withheld. Such indemnity shall remain in full
force and effect regardless of any investigation made by or on behalf of the Indemnified Person and shall survive the transfer
of the Registrable Securities by the Investor pursuant to Section 9.

b.                 
Promptly after receipt by an Indemnified Person under this Section 6 of notice of the commencement of any action or proceeding
(including any governmental action or proceeding) involving a Claim, such Indemnified Person shall, if a Claim in respect thereof
is to be made against the Company under this Section 6, deliver to the Company a written notice of the commencement thereof,
and the Company shall have the right to participate in, and, to the extent the Company so desires, to assume control of the defense
thereof with counsel mutually satisfactory to the Company and to the Indemnified Person; provided, however, that an Indemnified
Person shall have the right to retain its own counsel with the fees and expenses to be paid by the Company, if, in the reasonable
opinion of counsel retained by the Company, the representation by such counsel of the Indemnified Person and the Company would
be inappropriate due to actual or potential differing interests between such Indemnified Person and any other party represented
by such counsel in such proceeding. The Indemnified Person shall cooperate fully with the Company in connection with any negotiation
or defense of any such action or Claim by the Company and shall furnish to the Company all information reasonably available to
the Indemnified Person which relates to such action or Claim. The indemnifying party shall keep the Indemnified Person fully apprised
at all times as to the status of the defense or any settlement negotiations with respect thereto. The Company shall not be liable
for any settlement of any action, Claim or proceeding effectuated without its written consent, provided, however, that the Company
shall not unreasonably withhold, delay or condition its consent. The Company shall not, without the consent of the Indemnified
Person, consent to entry of any judgment or enter into any settlement or other compromise which does not include as an unconditional
term thereof the giving by the claimant or plaintiff to such Indemnified Person of a release from all liability in respect to
such Claim or litigation. Following indemnification as provided for hereunder, the Company shall be subrogated to all rights of
the Indemnified Person with respect to all third parties, firms or corporations relating to the matter for which indemnification
has been made. The failure to deliver written notice to the Company within a reasonable time of the commencement of any such action
shall not relieve the Company of any liability to the Indemnified Person under this Section 6, except to the extent that
the Company is prejudiced in its ability to defend such action.

c.                  
The indemnification required by this Section 6 shall be made by periodic payments of the amount thereof during the course
of the investigation or defense, as and when bills are received or Indemnified Damages are incurred.

d.                 
The indemnity agreements contained herein shall be in addition to (i) any cause of action or similar right of the Indemnified
Person against the Company or others, and (ii) any liabilities the Company may be subject to pursuant to the law.

 7. CONTRIBUTION.

 

To
the extent any indemnification by the Company is prohibited or limited by law, the Company agrees to make the maximum contribution
with respect to any amounts for which it would otherwise be liable under Section 6 to the fullest extent permitted by law.

 8. ASSIGNMENT OF REGISTRATION RIGHTS.

 

The
Company shall not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Buyer,
or any Investor as assignee pursuant to this Section 9. The Buyer, or any Investor, may not assign its rights under this
Agreement without the written consent of the Company other than to an affiliate of such Investor.

 9. AMENDMENT OF REGISTRATION RIGHTS.

 

No
provision of this Agreement may be (i) amended other than by a written instrument signed by both parties hereto or (ii) waived
other than in a written instrument signed by the party against whom enforcement of such waiver is sought. Failure of any party
to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy, shall
not operate as a waiver thereof.

 10. MISCELLANEOUS.

 

a.                  
A Person is deemed to be a holder of Registrable Securities whenever such Person owns or is deemed to own of record such Registrable
Securities. If the Company receives conflicting instructions, notices or elections from two or more Persons with respect to the
same Registrable Securities, the Company shall act upon the basis of instructions, notice or election received from the registered
owner of such Registrable Securities.

b.                 
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must
be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when
sent by email (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending
party); or (iii) one (1) business day after deposit with a nationally recognized overnight delivery service, in each case properly
addressed to the party to receive the same. The addresses for such communications shall be:

If
to the Company:

NuGenerex
Immuno-Oncology Inc.

10102
USA Today Way

Miramar,
FL 33025

Attention:
Joseph Moscato, CEO

E-mail:
jmoscato@nugenerex.com

Phone:
800-391-6755

NuGenerex
Immuno-Oncology Inc.

Anthony
S. Crisci, Esq., CPA

Chief
Legal Officer

E-mail:
acrisci@nugenerex.com

With
a copy (which shall not constitute notice) to:

Carmel,
Milazzo & Feil LLP

55
West 39th Street, 18th Flr

New
York, NY 10018

Attention:
Jeffrey P. Wofford

E-mail:
jwofford@cmfllp.com

If
to the Investor:

Oasis
Capital, LLC

208
Ponce de Leon Ave, Suite 1600

San
Juan, PR 00918

E-mail:
adam@oasis-cap.com

Attention:
Adam Long, Managing Partner

with
a copy to (that shall not constitute notice)

Nason,
Yeager, Gerson, Harris & Fumero, P.A.

3001
PGA Boulevard, Suite 305

Palm
Beach Gardens, FL 33410

E-mail:
bbernstein@nasonyeager.com

Attention:
Brian Bernstein, Esq.

or
at such other address and/or email address and/or to the attention of such other person as the recipient party has specified by
written notice given to each other party three (3) business days prior to the effectiveness of such change. Written confirmation
of receipt (A) given by the recipient of such notice, consent, waiver or other communication, (B) mechanically or electronically
generated by the sender’s email account containing the time, date, recipient email address, as applicable, and an image
of the first page of such transmission or (C) provided by a nationally recognized overnight delivery service, shall be rebuttable
evidence of personal service, receipt by email or receipt from a nationally recognized overnight delivery service in accordance
with clause (i), (ii) or (iii) above, respectively.

c.                  
All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the
internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether
of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than
the State of New York.

d.                 
 Any disputes, claims, or controversies hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein shall be referred to and resolved solely and exclusively by binding arbitration to be conducted before the Judicial Arbitration
and Mediation Service (“JAMS”), or its successor pursuant the expedited procedures set forth in the JAMS Comprehensive
Arbitration Rules and Procedures (the “Rules”), including Rules 16.1 and 16.2 of those Rules. The arbitration
shall be held in New York, New York, before a tribunal consisting of three (3) arbitrators each of whom will be selected in accordance
with the “strike and rank” methodology set forth in Rule 15. Either party to this Agreement may, without waiving any
remedy under this Agreement, seek from any federal or state court sitting in the State of New York any interim or provisional
relief that is necessary to protect the rights or property of that party, pending the establishment of the arbitral tribunal.
The costs and expenses of such arbitration shall be paid by and be the sole responsibility of the Company, including but not limited
to the Buyer’s attorneys’ fees and each arbitrator’s fees. The arbitrators’ decision must set forth a
reasoned basis for any award of damages or finding of liability. The arbitrators’ decision and award will be made and delivered
as soon as reasonably possibly and in any case within sixty (60) days’ following the conclusion of the arbitration hearing
and shall be final and binding on the parties and may be entered by any court having jurisdiction thereof.

e.                  
If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability
shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability
of any provision of this Agreement in any other jurisdiction.

f.                   
EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION
OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

g.                 
This Agreement and the Purchase Agreement constitute the entire agreement among the parties hereto with respect to the subject
matter hereof and thereof. There are no restrictions, promises, warranties or undertakings, other than those set forth or referred
to herein and therein. This Agreement and the Purchase Agreement supersede all prior agreements and understandings among the parties
hereto with respect to the subject matter hereof and thereof.

h.                 
Subject to the requirements of Section 9, this Agreement shall inure to the benefit of and be binding upon the successors
and permitted assigns of each of the parties hereto.

i.                   
The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.

j.                   
This Agreement may be executed in identical counterparts, each of which shall be deemed an original but all of which shall constitute
one and the same agreement. This Agreement, once executed by a party, may be delivered to the other party hereto by facsimile
transmission or by e-mail in a “.pdf” format data file of a copy of this Agreement bearing the signature of the party
so delivering this Agreement.

k.                 
Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver
all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry
out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

l.                   
The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent and
no rules of strict construction will be applied against any party.

m.               
This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns, and is
not for the benefit of, nor may any provision hereof be enforced by, any other Person.

*
* * * * *

    	 	1	 

     

    

 

IN
WITNESS WHEREOF, the parties have caused this Agreement to be duly executed as of the Execution Date.

	 	THE COMPANY:
	 	 
	 	NUGENEREX IMMUNO-ONCOLOGY INC.
	 	 
	 	By: /s/Joseph Moscato
	 	Name: Joseph Moscato
	 	Title: Chief Executive Officer
	 	 
	 	BUYER:
	 	 
	 	OASIS CAPITAL, LLC
	 	 
	 	By: /s/Adam Long
	 	Name: Adam Long
	 	Title: Managing Partner

 

    	 	2	 

     

    

EXHIBIT
A

TO
REGISTRATION RIGHTS AGREEMENT

FORM
OF NOTICE OF EFFECTIVENESS

OF
REGISTRATION STATEMENT

[__________]
[___], 2020

Securities
Transfer Corporation.

2901
N Dallas Prky

Suite
380

Plano,
TX 75093

 

Re:
EFFECTIVENESS OF REGISTRATION STATEMENT

Ladies
and Gentlemen:

We
are counsel to NUGENEREX IMMUNO-ONCOLOGY INC., a Delaware corporation (the “Company”), and have represented
the Company in connection with that certain Equity Purchase Agreement, dated as of June 29, 2020 (the “Purchase Agreement”),
entered into by and between the Company and Oasis Capital, LLC (the “Buyer”) pursuant to which the Company
has agreed to issue to the Buyer shares of the Company’s Common Stock, $0.001 par value (the “Common Stock”),
in an amount up to Fifty Million Dollars ($50,000,000.00) (the “Put Shares”), in accordance with the terms
of the Purchase Agreement. In connection with the transactions contemplated by the Purchase Agreement, the Company has registered
with the U.S. Securities & Exchange Commission the following shares of Common Stock:

 (1) Put Shares to be issued to the Buyer upon purchase from the Company by the Buyer from time to time in accordance with the Purchase Agreement; and

 

(2)       300,000
Commitment Shares which were issued to the Buyer pursuant to the Purchase Agreement.

Pursuant
to the Purchase Agreement, the Company also has entered into a Registration Rights Agreement, of even date with the Purchase Agreement
with the Buyer (the “Registration Rights Agreement”) pursuant to which the Company agreed, among other things,
to register the Put Shares and the Commitment Shares under the Securities Act of 1933, as amended (the “Securities Act”).
In connection with the Company’s obligations under the Purchase Agreement and the Registration Rights Agreement, on [__________]
[___], 2020, the Company filed a Registration Statement (File No. 333-[]) (the “Registration Statement”)
with the Securities and Exchange Commission (the “SEC”) relating to the resale of the Put Shares and the Commitment
Shares.

In
connection with the foregoing, we advise you that a member of the SEC’s staff has advised us by telephone that the SEC has
entered an order declaring the Registration Statement effective under the Securities Act at [] [A.M./P.M.] on [],
2020 and we have no knowledge, after telephonic inquiry of a member of the SEC’s staff, that any stop order suspending its
effectiveness has been issued or that any proceedings for that purpose are pending before, or threatened by, the SEC and the Put
Shares are available for resale under the Securities Act pursuant to the Registration Statement and may be issued without any
restrictive legend.

Very
truly yours,

[Company
Counsel]

By:       

cc:Oasis
Capital, LLC

    	 	3EQUITY
PURCHASE AGREEMENT

THIS
EQUITY PURCHASE AGREEMENT (this “Agreement”) is entered into as of July 14, 2020 (the “Execution
Date”), by and between NuGenerex Immuno-Oncology Inc., a Delaware corporation (the “Company”), and
Oasis Capital, LLC, a Puerto Rico limited liability company (the “Investor”).

RECITALS

WHEREAS,
the parties desire that, upon the terms and subject to the conditions contained herein, the Company shall issue and sell to the
Investor, from time to time as provided herein, and the Investor shall purchase from the Company up to Fifty Million Dollars ($50,000,000.00)
of the Company’s Common Stock (as defined below);

NOW,
THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the Company and the Investor hereby agree as follows:

Article
I

CERTAIN DEFINITIONS

Section
1.1               RECITALS.
The parties acknowledge and agree that the recitals set forth above are true and correct and are hereby incorporated in and made
a part of this Agreement. 

Section
1.2               DEFINED
TERMS. As used in this Agreement, the following terms shall have the following meanings specified or indicated (such meanings
to be equally applicable to both the singular and plural forms of the terms defined):

“Agreement”
shall have the meaning specified in the preamble hereof.

“Available
Amount” means, initially, the Maximum Commitment Amount, which amount shall be reduced by the Investment Amount following
each successful Closing, each time the Investor purchases shares of Common Stock pursuant to an Option 1 Put or Option 2 Put.

“Average
Daily Trading Volume” shall mean the average trading volume of the Company’s Common Stock in the ten (10) Trading
Days immediately preceding the respective Put Date.

“Bankruptcy
Law” means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors.

“Claim
Notice” shall have the meaning specified in Section 9.3(a).

“Clearing
Costs” shall mean all of the Investor’s broker and Transfer Agent fees.

“Clearing
Date” shall be the date on which the Investor receives the Put Shares as DWAC Shares in its brokerage account.

“Closing”
shall mean one of the closings of a purchase and sale of shares of Common Stock pursuant to Section 2.3.

“Closing
Certificate” shall mean the closing “Officer’s Certificate” of the Company in the form of Exhibit
B hereto.

“Closing
Date” shall mean the date of any Closing hereunder.

"Commitment
Period” shall mean the period commencing on the Execution Date, and ending on the earlier of (i) the date on which the
Investor shall have purchased Put Shares pursuant to this Agreement equal to the Maximum Commitment Amount, (ii) July ___, 2023,
or (iii) written notice of termination by the Company to the Investor (which shall not occur at any time that the Investor holds
any of the Put Shares).

“Commitment
Shares” means 300,000 shares of Common Stock issued by the Company to the Investor pursuant to Section 6.5 having
an aggregate market value, based on the estimated initial public offering price of $5.00/share, of $1,500,000.00, and adjusted
for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction.

“Common
Stock” shall mean the Company’s common stock, $0.001 par value per share, and any shares of any other class of
common stock whether now or hereafter authorized, having the right to participate in the distribution of dividends (as and when
declared) and assets (upon liquidation of the Company).

“Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
Common Stock.

“Company”
shall have the meaning specified in the preamble to this Agreement.

“Confidential
Information” means any information disclosed by either party to this Agreement, or their affiliates, agents or representatives,
to the other party to this Agreement, either directly or indirectly, in writing, orally or by inspection of tangible objects (including,
without limitation, documents, formulae, business information, trade secrets, technology, strategies. prototypes, samples, plant
and equipment), which may or may not be designated as “Confidential,” “Proprietary” or some similar designation.
Information communicated orally shall be considered Confidential Information. Confidential Information may also include information
disclosed by third parties. Confidential Information shall not, however, include any information which (i) was publicly known
and made generally available in the public domain prior to the time of disclosure by the disclosing party; (ii) becomes publicly
known and made generally available after disclosure by the disclosing party to the receiving party through no fault, action or
inaction of the receiving party; (iii) is already in the possession of the receiving party at the time of disclosure by the disclosing
party as shown by the receiving party’s files and records immediately prior to the time of disclosure; (iv) is obtained
by the receiving party from a third party without a breach of such third party’s obligations of confidentiality; (v) is
independently developed by the receiving party without use of or reference to the disclosing party’s Confidential Information,
as shown by documents and other competent evidence in the receiving party’s possession; or (vi) is required by law to be
disclosed by the receiving party, provided that the receiving party gives the disclosing party prompt written notice of such requirement
prior to such disclosure and assistance in obtaining an order protecting the information from public disclosure.

“Current
Report” shall have the meaning set forth in Section 6.4.

“Custodian”
means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.

“Damages”
shall mean any loss, claim, damage, liability, cost and expense (including, without limitation, reasonable attorneys’ fees
and disbursements and costs and expenses of expert witnesses and investigation).

“Dispute
Period” shall have the meaning specified in Section 9.3(a).

“Disqualification
Event” shall have the meaning specified in Section 4.27.

“DTC”
shall mean The Depository Trust Company, or any successor performing substantially the same function for the Company.

“DTC/FAST
Program” shall mean the DTC’s Fast Automated Securities Transfer Program.

“DWAC”
shall mean Deposit Withdrawal at Custodian as defined by the DTC.

“DWAC
Eligible” shall mean that (a) the Common Stock is eligible at DTC for full services pursuant to DTC’s operational
arrangements, including, without limitation, transfer through DTC’s DWAC system, (b) the Company has been approved (without
revocation) by the DTC’s underwriting department, (c) the Transfer Agent is approved as an agent in the DTC/FAST Program,
(d) the Commitment Shares or Put Shares, as applicable, are otherwise eligible for delivery via DWAC, and (e) the Transfer Agent
does not have a policy prohibiting or limiting delivery of the Put Shares or Commitment Shares, as applicable, via DWAC.

“DWAC
Shares” means shares of Common Stock that are (i) issued in electronic form, (ii) freely tradable and transferable and
without restriction on resale and (iii) timely credited by the Company to the Investor’s or its designee’s specified
DWAC account with DTC under the DTC/FAST Program, or any similar program hereafter adopted by DTC performing substantially the
same function.

“Environmental
Laws” shall have the meaning set forth in Section 4.14.

“Exchange
Act” shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

“Execution
Date” shall have the meaning set forth in the preamble to this Agreement.

“FINRA”
shall mean the Financial Industry Regulatory Authority, Inc.

“Floor
Price” shall mean $1 per share, which shall be adjusted for any reorganization, recapitalization, non-cash dividend,
stock split or other similar transaction and, effective upon the consummation of any such reorganization, recapitalization, non-cash
dividend, stock split or other similar transaction, the Floor Price shall mean the lower of (i) the adjusted price and (ii) $1.

“Indemnified
Party” shall have the meaning specified in Section 9.2.

“Indemnifying
Party” shall have the meaning specified in Section 9.2.

“Indemnity
Notice” shall have the meaning specified in Section 9.3(b).

“Intellectual
Property” shall mean all trademarks, trademark applications, trade names, service marks, service mark registrations,
service names, patents, patent applications, patent rights, copyrights, inventions, licenses, approvals, government authorizations,
trade secrets or other intellectual property rights.

“Investment
Amount” shall mean the dollar value equal to the amount of Put Shares referenced in the Put Notice multiplied by the
Option 1 Purchase Price or Option 2 Purchase Price (as applicable) minus the Clearing Costs.

“Investor”
shall have the meaning specified in the preamble to this Agreement.

“Issuer
Covered Person” shall have the meaning specified in Section 4.27.

“Lien”
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or any other restriction.

“Material
Adverse Effect” shall mean any effect on the business, operations, properties, or financial condition of the Company
and/or the Subsidiaries that is material and adverse to the Company and/or the Subsidiaries and/or any condition, circumstance,
or situation that would prohibit or otherwise materially interfere with the ability of the Company and/or the Subsidiaries to
enter into and/or perform its obligations under any Transaction Document.

“Maximum
Commitment Amount” shall mean Fifty Million Dollars ($50,000,000.00).

“Option
1 Maximum Put Amount” shall mean:

(a)               
if, on the Put Date, the closing bid price of
the Common Stock on the Principal Market is below $6.00, then “Option 1 Maximum Put Amount” shall mean the lesser
of (i) 25,000 shares, or (ii) twenty percent (20%) of the Average Daily Trading Volume; or

(b)               
if, on the Put Date, the closing bid price of
the Common Stock on the Principal Market is $6.00 or greater but less than $7.00, then “Option 1 Maximum Put Amount”
shall mean the lesser of (i) 30,000 shares, or (ii) twenty percent (20%) of the Average Daily Trading Volume; or

(c)               
if, on the Put Date, the closing bid price of
the Common Stock on the Principal Market is $7.00 or greater, then “Option 1 Maximum Put Amount” shall mean the lesser
of (i) 40,000 shares, or (ii) twenty percent (20%) of the Average Daily Trading Volume.

“Option
1 Purchase Price” shall mean the lesser of (i) the one (1) lowest traded price of the Common Stock on the Principal
Market on the Clearing Date, or (ii) the average of the three (3) lowest closing sale prices of the Common Stock on the Principal
Market during the Option 1 Valuation Period, as reported by Bloomberg Finance L.P. or other reputable source.

“Option
1 Put” shall mean the right of the Company to require the Investor to purchase shares of Common Stock at the Option
1 Purchase Price, subject to the terms and conditions of this Agreement.

“Option
1 Valuation Period” shall mean the period of twelve (12) consecutive Trading Days immediately preceding the Clearing
Date associated with the applicable Put Notice during which the Option 1 Purchase Price of the Common Stock is valued.

“Option
2 Maximum Put Amount” shall mean the lesser of (i) such amount that equals ten percent (10%) of the daily trading volume
of the Common Stock on the Put Date, and (ii) a number of shares of Common Stock equal to (x) Five Hundred Thousand Dollars ($500,000.00)
divided by (y) the Option 2 Purchase Price.

“Option
2 Purchase Price” shall mean the lesser of (i) 92% of the one (1) lowest traded price of the Common Stock on the Principal
Market during the Option 2 Valuation Period as reported by Bloomberg Finance L.P. or other reputable source, or (ii) 92% of the
VWAP on the Clearing Date, or (iii) 92% of the closing bid price of the Common Stock on the Principal Market on the Clearing Date.

“Option
2 Put” shall mean the right of the Company to require the Investor to purchase shares of Common Stock at the Option
2 Purchase Price, subject to the terms and conditions of this Agreement.

“Option
2 Valuation Period” shall mean the period of ten (10) consecutive Trading Days immediately preceding the Put Date associated
with the applicable Put Notice during which the Option 2 Purchase Price of the Common Stock is valued.

“Person”
shall mean an individual, a corporation, a partnership, an association, a trust or other entity or organization, including a government
or political subdivision or an agency or instrumentality thereof.

“Principal
Market” shall mean the NASDAQ stock market or any other national securities exchange registered with the SEC.

“Put
Date” shall mean any Trading Day during the Commitment Period that a Put Notice is deemed delivered pursuant to Section
2.2(b).

“Put
Notice” shall mean a written notice, substantially in the form of Exhibit A hereto, addressed to the Investor
and setting forth the amount of Put Shares which the Company intends to require the Investor to purchase pursuant to the terms
of this Agreement.

“Put
Shares” shall mean all shares of Common Stock issued, or that the Company shall be entitled to issue, per any applicable
Put Notice in accordance with the terms and conditions of this Agreement.

“Registration
Rights Agreement” means that agreement in the form attached hereto as Exhibit D.

“Registration
Statement” shall have the meaning specified in Section 6.4.

“Regulation
D” shall mean Regulation D promulgated under the Securities Act.

“Rule
144” shall mean Rule 144 promulgated under the Securities Act or any similar provision then in force under the Securities
Act.

“SEC”
shall mean the United States Securities and Exchange Commission.

“SEC
Documents” shall have the meaning specified in Section 4.5.

“Securities”
means, collectively, the Put Shares and the Commitment Shares.

“Securities
Act” shall mean the Securities Act of 1933, as amended.

“Short
Sales” shall mean all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act.

“Subsidiary”
or “Subsidiaries” means any Person the Company wholly-owns or controls, or in which the Company, directly or
indirectly, owns a majority of the voting stock or similar voting interest, in each case that would be disclosable pursuant to
Item 601(b)(21) of Regulation S-K promulgated under the Securities Act.

“Third
Party Claim” shall have the meaning specified in Section 9.3(a).

“Trading
Day” shall mean a day on which the Principal Market shall be open for business.

“Transaction
Documents” shall mean this Agreement, the Registration Rights Agreement and all schedules and exhibits hereto and thereto.

“Transfer
Agent” shall mean Securities Transfer Corporation, the current transfer agent of the Company, and any successor transfer
agent of the Company.

“Transfer
Agent Instruction Letter” means the letter from the Company to the Transfer Agent which instructs the Transfer Agent
to issue the Put Shares and the Commitment Shares pursuant to the Transaction Documents, in the form of Exhibit C attached
hereto.

“VWAP”
shall mean for any date, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on such national exchange on which the Common Stock is then listed or quoted for trading as reported by Bloomberg L.P. or Quotestream,
a product of QuoteMedia, Inc. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)).

Article
II

PURCHASE AND SALE OF COMMON STOCK

Section
2.1               PUTS.
Upon the terms and conditions set forth herein (including, without limitation, the provisions of Article VII), the Company
shall have the right, but not the obligation, to direct the Investor, to process an:

(a)               
Option 1 Put by its delivery to the Investor
of a Put Notice from time to time during the Commitment Period, to purchase Put Shares, provided that notwithstanding any other
terms of this Agreement, in each instance, (i) the Investment Amount is not more than the Option 1 Maximum Put Amount for any
Option 1 Put, (ii) the aggregate Investment Amount of all Option 1 Puts and Option 2 Puts shall not exceed the Maximum Commitment
Amount; (iii) the Trading Day prior to the subject Clearing Date did not have the lowest VWAP of the Common Stock out of the prior
ten (10) consecutive Trading Days, (iv) at least two (2) Trading Days have lapsed since the most recent Clearing Date of an Option
1 Put, (v) the aggregate Investment Amount of the Option 1 Put on any particular Put Date or Clearing Date does not exceed $500,000.00,
and (vi) the lowest traded price of the Common Stock in the five (5) Trading Days immediately preceding the respective Put Date
must exceed the Floor Price; and 

(b)               
Option 2 Put by its delivery to the Investor
of a Put Notice from time to time during the Commitment Period, to purchase Put Shares, provided that notwithstanding any other
terms of this Agreement, in each instance, (i) an Option 1 Put has been previously and effectively processed and its Clearing
Date is the same day as the Put Notice for the subject Option 2 Put, (ii) the Investment Amount is not more than the Option 2
Maximum Put Amount for any Option 2 Put, (iii) the aggregate Investment Amount of all Option 1 Puts and Option 2 Puts shall not
exceed the Maximum Commitment Amount, (iv) the aggregate Investment Amount of the Option 2 Put on any particular Put Date or Clearing
Date does not exceed $500,000.00, (v) if all shares of Common Stock resulting from prior submitted Put Notices for Option 1 Puts
have been delivered, and (vi) the lowest traded price of the Common Stock in the five (5) Trading Days immediately preceding the
respective Put Date must exceed the Floor Price.

Section
2.2               MECHANICS.

(a)               
PUT NOTICE. At any time and from time
to time during the Commitment Period, except as provided in this Agreement, the Company may cause an Option 1 Put or an Option
2 Put by delivering a Put Notice to the Investor, subject to satisfaction of the conditions set forth in Section 2.1, Section
7.2 and otherwise provided in this Agreement. The Company shall deliver, or cause to be delivered, the Put Shares as DWAC
Shares to the Investor within two (2) Trading Days following the Put Date.

(b)               
DATE OF DELIVERY OF PUT NOTICE. A Put
Notice shall be deemed delivered on (i) the Trading Day it is received by e-mail by the Investor if such notice is received on
or prior to 8:30 a.m. EST or (ii) the immediately succeeding Trading Day if it is received by e-mail after 8:30 a.m. EST on a
Trading Day or at any time on a day which is not a Trading Day.

Section
2.3               CLOSINGS.

(a)               
TIMING. The Closing of an Option 1 Put
shall occur within one (1) Trading Day following the end of the respective Option 1 Valuation Period, whereby the Investor shall
deliver the Investment Amount by wire transfer of immediately available funds to an account designated by the Company. The Closing
of an Option 2 Put shall occur within one (1) Trading Day following the Clearing Date, whereby the Investor shall deliver the
Investment Amount by wire transfer of immediately available funds to an account designated by the Company. In addition, on or
prior to any such Closing, each of the Company and the Investor shall deliver to each other all documents, instruments and writings
required to be delivered or reasonably requested by either of them pursuant to this Agreement in order to implement and effect
the transactions contemplated herein.

(b)               
RETURN OF SURPLUS. If the value of the
Put Shares delivered to the Investor causes the Company to exceed the Maximum Commitment Amount, then the Investor shall return
to the Company the surplus amount of Put Shares associated with such Option 1 Put or Option 2 Put, and the Option 1 Purchase Price
or Option 2 Purchase Price with respect to such Option 1 Put or Option 2 Put shall be reduced by any Clearing Costs related to
the return of such Put Shares.

(c)               
RESALES DURING VALUATION PERIOD. The parties
acknowledge and agree that during the Option 1 Valuation Period or Option 2 Valuation Period (as applicable), the Investor may
contract for, or otherwise effect, the resale of the subject purchased Put Shares to third-parties. 

Article
III

REPRESENTATIONS AND WARRANTIES OF INVESTOR

The
Investor represents and warrants to the Company that:

Section
3.1               INTENT.
The Investor is entering into this Agreement for its own account, and the Investor has no present arrangement (whether or not
legally binding) at any time to sell the Securities to or through any Person in violation of the Securities Act or any applicable
state securities laws; provided, however, that the Investor reserves the right to dispose of the Securities at any
time in accordance with federal and state securities laws applicable to such disposition.

Section
3.2               NO
LEGAL ADVICE FROM THE COMPANY. The Investor acknowledges that it has had the opportunity to review this Agreement and the
transactions contemplated by this Agreement with its own legal counsel and investment and tax advisors. Except with respect to
the representations, warranties and covenants contained in this Agreement, the Investor is relying solely on such counsel and
advisors and not on any statements or representations of the Company or any of its representatives or agents for legal, tax or
investment advice with respect to this investment, the transactions contemplated by this Agreement or the securities laws of any
jurisdiction.

Section
3.3               ACCREDITED
INVESTOR. The Investor is an accredited investor as defined in Rule 501(a)(3) of Regulation D, and the Investor has such experience
in business and financial matters that it is capable of evaluating the merits and risks of an investment in the Securities. The
Investor acknowledges that an investment in the Securities is speculative and involves a high degree of risk.

Section
3.4               AUTHORITY.
The Investor has the requisite power and authority to enter into and perform its obligations under this Agreement and the other
Transaction Documents and to consummate the transactions contemplated hereby and thereby. The execution and delivery of this Agreement
and the other Transaction Documents and the consummation by it of the transactions contemplated hereby and thereby have been duly
authorized by all necessary action and no further consent or authorization of the Investor is required. Each Transaction Document
to which it is a party has been duly executed by the Investor, and when delivered by the Investor in accordance with the terms
hereof, will constitute the valid and binding obligation of the Investor enforceable against it in accordance with its terms,
subject to applicable bankruptcy, insolvency, or similar laws relating to, or affecting generally the enforcement of, creditors’
rights and remedies or by other equitable principles of general application.

Section
3.5               NOT
AN AFFILIATE. To the Investor’s knowledge, the Investor is not an officer, director or “affiliate” (as such
term is defined in Rule 405 of the Securities Act) of the Company.

Section
3.6               ORGANIZATION
AND STANDING. The Investor is an entity duly formed, validly existing and in good standing under the laws of the jurisdiction
of its formation with full right, limited liability company power and authority to enter into and to consummate the transactions
contemplated by this Agreement and the other Transaction Documents.

Section
3.7               ABSENCE
OF CONFLICTS. The execution and delivery of this Agreement and the other Transaction Documents, and the consummation of the
transactions contemplated hereby and thereby and compliance with the requirements hereof and thereof, will not (a) violate any
law, rule, regulation, order, writ, judgment, injunction, decree or award binding on the Investor, (b) violate any provision of
any indenture, instrument or agreement to which the Investor is a party or is subject, or by which the Investor or any of its
assets is bound, or conflict with or constitute a material default thereunder, (c) result in the creation or imposition of any
lien pursuant to the terms of any such indenture, instrument or agreement, or constitute a breach of any fiduciary duty owed by
the Investor to any third party, or (d) require the approval of any third-party (that has not been obtained) pursuant to any material
contract, instrument, agreement, relationship or legal obligation to which the Investor is subject or to which any of its assets,
operations or management may be subject.

Section
3.8               DISCLOSURE;
ACCESS TO INFORMATION. The Investor had an opportunity to review copies of the SEC Documents filed on behalf of the Company
and has had access to all publicly available information with respect to the Company; provided, however, that the Investor makes
no representation or warranty hereunder with respect to any SEC Document and is relying on the representations and warranties
of the Company in Article IV with respect to the SEC Documents.

Section
3.9               MANNER
OF SALE. At no time was the Investor presented with or solicited by or through any leaflet, public promotional meeting, television
advertisement or any other form of general solicitation or advertisement regarding the Securities.

Article
IV

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

The
Company represents and warrants to the Investor that, except as set forth in the disclosure schedules hereto that as of the Execution
Date and at each Closing Date:

Section
4.1               ORGANIZATION
OF THE COMPANY. The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the
state of Delaware, with the requisite power and authority to own and use its properties and assets and to carry on its business
as currently conducted. Each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in
good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority
to own and use its properties and assets and to carry on its business as currently conducted. Each of the Company and the Subsidiaries
is not in violation or default of any of the provisions of its respective certificate or articles of incorporation, bylaws or
other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and
is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted
or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as
the case may be, could not have or reasonably be expected to result in a Material Adverse Effect and no proceeding has been instituted
in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.

Section
4.2               AUTHORITY.
The Company has the requisite corporate power and authority to enter into and perform its obligations under this Agreement and
the other Transaction Documents. The execution and delivery of this Agreement and the other Transaction Documents by the Company
and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary corporate
action and no further consent or authorization of the Company or its board of directors or stockholders is required. Each of this
Agreement and the other Transaction Documents has been duly executed and delivered by the Company and constitutes a valid and
binding obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability
may be limited by applicable bankruptcy, insolvency, or similar laws relating to, or affecting generally the enforcement of, creditors’
rights and remedies or by other equitable principles of general application.

Section
4.3               CAPITALIZATION.
As of the Execution Date, the authorized capital stock of the Company is as set forth in the SEC Documents. Except as set forth
in the SEC Documents or on Schedule 4.3, the Company has not issued any capital stock since its most recently filed periodic
report under the Exchange Act, other than pursuant to the exercise of employee stock options under the Company’s stock option
plans, the issuance of shares of Common Stock to employees pursuant to the Company’s employee stock purchase plans and pursuant
to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report
under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right
to participate in the transactions contemplated by the Transaction Documents. Except as set forth in the SEC Documents or on Schedule
4.3, and except as a result of the purchase and sale of the Securities, there are no outstanding options, warrants, scrip
rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible
into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire any shares of Common Stock,
or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue
additional shares of Common Stock or Common Stock Equivalents. The issuance and sale of the Securities will not obligate the Company
to issue shares of Common Stock or other securities to any Person (other than the Investor) and will not result in a right of
any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities. There
are no stockholders agreements, voting agreements or other similar agreements with respect to the Company’s capital stock
to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders.

Section
4.4               LISTING
AND MAINTENANCE REQUIREMENTS. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the
Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act, nor has the Company received any notification that the SEC is contemplating terminating
such registration. As of each Closing Date, the Company will not, in the twelve (12) months preceding such Closing Date, received
notice from the Principal Market to the effect that the Company is not in compliance with the listing or maintenance requirements
of such Principal Market. Except as set forth on Schedule 4.4(b), the Company is, and has no reason to believe that it
will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements.

Section
4.5               SEC
DOCUMENTS; DISCLOSURE. The Company has filed all reports, schedules, forms, statements and other documents required to be
filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for
the one (1) year preceding the Execution Date (or such shorter period as the Company was required by law or regulation to file
such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being
collectively referred to herein as the “SEC Documents”) on a timely basis or has received a valid extension
of such time of filing and has filed any such SEC Documents prior to the expiration of any such extension. As of their respective
dates, the SEC Documents complied in all material respects with the requirements of the Securities Act and the Exchange Act, as
applicable, and other federal laws, rules and regulations applicable to such SEC Documents, and none of the SEC Documents when
filed contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary
in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The financial
statements of the Company included in the SEC Documents comply as to form and substance in all material respects with applicable
accounting requirements and the published rules and regulations of the SEC or other applicable rules and regulations with respect
thereto. Such financial statements have been prepared in accordance with generally accepted accounting principles applied on a
consistent basis during the periods involved (except (a) as may be otherwise indicated in such financial statements or the notes
thereto or (b) in the case of unaudited interim statements, to the extent they may not include footnotes or may be condensed or
summary statements) and fairly present in all material respects the financial position of the Company as of the dates thereof
and the results of operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal,
immaterial, year-end audit adjustments). There is no transaction, arrangement, or other relationship between the Company and an
unconsolidated or other off balance sheet entity that is not disclosed by the Company in its financial statements or otherwise
that would be reasonably likely to have a Material Adverse Effect. Except with respect to the material terms and conditions of
the transactions contemplated by the Transaction Documents, the Company confirms that neither it nor any other Person acting on
its behalf has provided the Investor or its agents or counsel with any information that it believes constitutes or might constitute
material, non-public information. The Company understands and confirms that the Investor will rely on the foregoing representation
in effecting transactions in securities of the Company.

Section
4.6               VALID
ISSUANCES. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction
Documents, will be validly issued, fully paid, and non-assessable, free and clear of all Liens imposed by the Company, other than
restrictions on transfer provided for in the Transaction Documents and under the Securities Act.

Section
4.7               NO
CONFLICTS. The execution, delivery and performance of this Agreement and the other Transaction Documents by the Company, and
the consummation by the Company of the transactions contemplated hereby and thereby, including, without limitation, the issuance
of the Put Shares and the Commitment Shares, do not and will not: (a) result in a violation of the Company’s or any Subsidiary’s
certificate or articles of incorporation, by-laws or other organizational or charter documents, (b) conflict with, or constitute
a material default (or an event that with notice or lapse of time or both would become a material default) under, result in the
creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination,
amendment, acceleration or cancellation of, any agreement, indenture, instrument or any “lock-up” or similar provision
of any underwriting or similar agreement to which the Company or any Subsidiary is a party, or (c) result in a violation of any
federal, state or local law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations)
applicable to the Company or any Subsidiary or by which any property or asset of the Company or any Subsidiary is bound or affected
(except for such conflicts, defaults, terminations, amendments, accelerations, cancellations and violations as would not, individually
or in the aggregate, have a Material Adverse Effect), nor is the Company otherwise in violation of, conflict with or in default
under any of the foregoing. The business of the Company is not being conducted in violation of any law, ordinance or regulation
of any governmental entity, except for possible violations that either singly or in the aggregate do not and will not have a Material
Adverse Effect. The Company is not required under federal, state or local law, rule or regulation to obtain any consent, authorization
or order of, or make any filing or registration with, any court or governmental agency in order for it to execute, deliver or
perform any of its obligations under this Agreement or the other Transaction Documents (other than any SEC, FINRA or state securities
filings that may be required to be made by the Company in connection with the issuance of the Commitment Shares or subsequent
to any Closing or any registration statement that may be filed pursuant hereto); provided that, for purposes of the representation
made in this sentence, the Company is assuming and relying upon the accuracy of the relevant representations and agreements of
Investor herein.

Section
4.8               NO
MATERIAL ADVERSE CHANGE. No event has occurred that would have a Material Adverse Effect on the Company or any Subsidiary
that has not been disclosed in subsequent SEC filings.

Section
4.9               LITIGATION
AND OTHER PROCEEDINGS. Except as set forth on Schedule 4.9, there are no actions, suits, investigations, inquiries
or proceedings pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any
of their respective properties, nor has the Company received any written or oral notice of any such action, suit, proceeding,
inquiry or investigation, which would have a Material Adverse Effect or would require disclosure under the Securities Act or the
Exchange Act. No judgment, order, writ, injunction or decree or award has been issued by or, to the knowledge of the Company,
requested of any court, arbitrator or governmental agency which would have a Material Adverse Effect. There has not been, and
to the knowledge of the Company, there is not pending or contemplated, any investigation by the SEC involving the Company, any
Subsidiary, or any current or former director or officer of the Company or any Subsidiary.

Section
4.10            REGISTRATION
RIGHTS. Except as set forth on Schedule 4.10, no Person (other than the Investor) has any right to cause the Company
to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.

Section
4.11            INVESTOR’S
STATUS. The Company acknowledges and agrees that the Investor is acting solely in the capacity of arm’s length purchaser
with respect to the Transaction Documents and the transactions contemplated hereby and thereby. The Company further acknowledges
that the Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to
the Transaction Documents and the transactions contemplated hereby and thereby and any advice given by the Investor or any of
its representatives or agents in connection with the Transaction Documents and the transactions contemplated hereby and thereby
is merely incidental to the Investor’s purchase of the Securities. The Company further represents to the Investor that the
Company’s decision to enter into the Transaction Documents has been based solely on the independent evaluation by the Company
and its representatives and advisors.

Section
4.12            NO
GENERAL SOLICITATION; NO INTEGRATED OFFERING. Neither the Company, any Subsidiary, nor any of their respective affiliates,
nor any Person acting on their behalf, has engaged in any form of general solicitation or general advertising (within the meaning
of Regulation D under the Securities Act) in connection with the offer or sale of the Securities. Neither the Company, any Subsidiary,
nor any of their respective affiliates, nor any Person acting on their behalf has, directly or indirectly, made any offers or
sales of any security or solicited any offers to buy any security, under circumstances that would require registration of the
offer and sale of any of the Securities under the Securities Act, whether through integration with prior offerings or otherwise,.
The issuance and sale of the Securities hereunder will not contravene the rules and regulations of the Principal Market.

Section
4.13            INTELLECTUAL
PROPERTY RIGHTS. The Company and each Subsidiary own or possess adequate rights or licenses to use all material trademarks,
trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses,
approvals, governmental authorizations, trade secrets and rights necessary to conduct their respective businesses as now conducted.
None of the Company’s, nor any Subsidiary’s Intellectual Property has expired or terminated, or, by the terms and
conditions thereof, could expire or terminate within three years from the date of this Agreement if such expiration or termination
could reasonably be expected to have a Material Adverse Effect. The Company does not have any knowledge of any infringement by
the Company and/or any Subsidiary of any material Intellectual Property of others, or of any such development of similar or identical
trade secrets or technical information by others, and there is no claim, action or proceeding being made or brought against, or
to the Company’s knowledge, being threatened against, the Company and/or any Subsidiary regarding the infringement of any
Intellectual Property, which could reasonably be expected to have a Material Adverse Effect.

Section
4.14            ENVIRONMENTAL
LAWS. To the Company’s knowledge, the Company and each Subsidiary (i) is in compliance with any and all applicable foreign,
federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous
or toxic substances or wastes, pollutants or contaminants (“Environmental Laws”), (ii) has received all permits,
licenses or other approvals required of it under applicable Environmental Laws to conduct its respective businesses and (iii)
is in compliance with all terms and conditions of any such permit, license or approval, except where, in each of the three foregoing
clauses, the failure to so comply could not reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect.

Section
4.15            TITLE.
Except as disclosed in the SEC Documents, the Company and each Subsidiary has good and marketable title in fee simple to all real
property owned by it and good and marketable title in all personal property owned by it that is material to the business of the
Company and each Subsidiary, in each case free and clear of all Liens and, except for Liens as do not materially affect the value
of such property and do not materially interfere with the use made and proposed to be made of such property by the Company or
any Subsidiary and Liens for the payment of federal, state or other taxes, the payment of which is neither delinquent nor subject
to penalties. Any real property and facilities held under lease by the Company or any Subsidiary is held under valid, subsisting
and enforceable leases with which the Company is in compliance with such exceptions as are not material and do not interfere with
the use made and proposed to be made of such property and buildings by the Company or any Subsidiary.

Section
4.16            INSURANCE.
The Company and each Subsidiary is insured by insurers of recognized financial responsibility against such losses and risks and
in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company and each
Subsidiary is engaged. Neither the Company, nor any Subsidiary has been refused any insurance coverage sought or applied for,
and the Company has no reason to believe that it or any Subsidiary will not be able to renew its existing insurance coverage as
and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business
at a cost that would not materially and adversely affect the condition, financial or otherwise, or the earnings, business or operations
of the Company, taken as a whole.

Section
4.17            REGULATORY
PERMITS. The Company and each Subsidiary possesses all material certificates, authorizations and permits issued by the appropriate
federal, state or foreign regulatory authorities necessary to conduct its businesses, and neither the Company, nor any Subsidiary
has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit.

Section
4.18            TAX
STATUS. The Company and each Subsidiary has made or filed all federal and state income and all other material tax returns,
reports and declarations required by any jurisdiction to which it is subject (unless and only to the extent that the Company has
set aside on its books provisions reasonably adequate for the payment of all unpaid and unreported taxes) and has paid all taxes
and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports
and declarations, except those being contested in good faith and has set aside on its books provision reasonably adequate for
the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are
no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the
Company know of no basis for any such claim.

Section
4.19            TRANSACTIONS
WITH AFFILIATES. Except as set forth in the SEC Documents, none of the officers or directors of the Company or any Subsidiary,
and to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction
with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement
or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or
from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any
entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or
partner, in each case in excess of the lesser of (i) $120,000 or (ii) one percent of the average of the Company’s total
assets at year end for the last two completed fiscal years, other than for (i) payment of salary or consulting fees for services
rendered, (ii) reimbursement for expenses incurred on behalf of the Company or any Subsidiary and (iii) other employee benefits,
including stock option agreements under any stock option plan of the Company.

Section
4.20            APPLICATION
OF TAKEOVER PROTECTIONS. The Company and its board of directors have taken or will take prior to the Execution Date all necessary
action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any
distribution under a rights agreement) or other similar anti-takeover provision under the articles of incorporation or the laws
of the state of its incorporation which is or could become applicable to the Investor as a result of the transactions contemplated
by this Agreement, including, without limitation, the Company’s issuance of the Securities and the Investor’s ownership
of the Securities.

Section
4.21            FOREIGN
CORRUPT PRACTICES. Neither the Company, any Subsidiary, nor to the knowledge of the Company, any agent or other Person acting
on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts,
entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to
foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any Person acting on
its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision
of the Foreign Corrupt Practices Act of 1977, as amended.

Section
4.22            SARBANES-OXLEY.
The Company is in compliance with all provisions of the Sarbanes-Oxley Act of 2002, as amended, which are applicable to it.

Section
4.23            CERTAIN
FEES. No brokerage or finder’s fees or commissions are or will be payable by the Company to any broker, financial advisor
or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated
by the Transaction Documents. The Investor shall have no obligation with respect to any fees or with respect to any claims made
by or on behalf of any Persons for fees of a type contemplated in this Section 4.23 that may be due in connection with
the transactions contemplated by the Transaction Documents.

Section
4.24            INVESTMENT
COMPANY. The Company is not an “investment company” within the meaning of the Investment Company Act of 1940,
as amended.

Section
4.25            ACCOUNTANTS.
The Company’s accountants are set forth in the SEC Documents and, to the knowledge of the Company, such accountants are
an independent registered public accounting firm as required by the Securities Act.

Section
4.26            NO
MARKET MANIPULATION. Neither the Company, nor any Subsidiary has, and to its knowledge no Person acting on either of their
behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation
of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased,
or, paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any
compensation for soliciting another to purchase any other securities of the Company.

Section
4.27            NO
DISQUALIFICATION EVENTS. None of the Company, any Subsidiary, any of their predecessors, any affiliated issuer, any director,
executive officer, other officer of the Company or any Subsidiary participating in the offering contemplated hereby, any beneficial
owner of 20% or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, nor
any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the
time of sale (each, an “Issuer Covered Person”) is subject to any of the “Bad Actor” disqualifications
described in Rule 506(d)(1) under the Securities Act (a “Disqualification Event”), except for a Disqualification
Event covered by Rule 506(d)(2) or (d)(3) under the Securities Act. The Company has exercised reasonable care to determine whether
any Issuer Covered Person is subject to a Disqualification Event.

Section
4.28            MONEY
LAUNDERING. The Company and each Subsidiary is in compliance with, and has not previously violated, the USA PATRIOT ACT of
2001 and all other applicable U.S. and non-U.S. anti-money laundering laws and regulations, including, but not limited to, the
laws, regulations and Executive Orders and sanctions programs administered by the U.S. Office of Foreign Assets Control, including,
but not limited, to (i) Executive Order 13224 of September 23, 2001 entitled, “Blocking Property and Prohibiting Transactions
With Persons Who Commit, Threaten to Commit, or Support Terrorism” (66 Fed. Reg. 49079 (2001)); and (ii) any regulations
contained in 31 CFR, Subtitle B, Chapter V.

Section
4.29            ILLEGAL
OR UNAUTHORIZED PAYMENTS; POLITICAL CONTRIBUTIONS. Neither the Company, nor any Subsidiary has, nor, to the best of the Company’s
knowledge (after reasonable inquiry of its officers and directors), any of the officers, directors, employees, agents or other
representatives of the Company, any Subsidiary or any other business entity or enterprise with which the Company is or has been
affiliated or associated, has, directly or indirectly, made or authorized any payment, contribution or gift of money, property,
or services, whether or not in contravention of applicable law, (a) as a kickback or bribe to any Person or (b) to any political
organization, or the holder of or any aspirant to any elective or appointive public office except for personal political contributions
not involving the direct or indirect use of funds of the Company.

Section
4.30            SHELL
COMPANY STATUS. The Company is not currently an issuer identified in Rule 144(i)(1)(i) under the Securities Act, is subject
to the reporting requirements of Section 13 or 15(d) of the Exchange Act, has filed all reports and other materials required to
be filed by Section 13 or 15(d) of the Exchange Act, as applicable during the preceding 12 months, and, as of a date at least
one year prior to the Execution Date, has filed current “Form 10 information” with the SEC (as defined in Rule 144(i)(3)
of the Securities Act) reflecting its status as an entity that is no longer an issuer described in Rule 144(i)(1)(i) of the Securities
Act.

Section
4.31            ABSENCE
OF SCHEDULES. In the event that on the Execution Date, the Company does not deliver any disclosure schedule contemplated by
this Agreement, the Company hereby acknowledges and agrees that (i) each such undelivered disclosure schedule shall be deemed
to read as follows: “Nothing to Disclose”, and (ii) the Investor has not otherwise waived delivery of such disclosure
schedule. 

Article
V

COVENANTS OF INVESTOR

Section
5.1               COMPLIANCE
WITH LAW; TRADING IN SECURITIES. The Investor’s trading activities with respect to shares of Common Stock will be in
compliance with all applicable state and federal securities laws and regulations and the rules and regulations of FINRA and the
Principal Market.

Section
5.2               SHORT
SALES AND CONFIDENTIALITY. Neither the Investor, nor any affiliate of the Investor acting on its behalf or pursuant to any
understanding with it, will execute any Short Sales during the period from the Execution Date to the end of the Commitment Period.
For the purposes hereof, and in accordance with Regulation SHO, the sale after delivery of a Put Notice of such number of shares
of Common Stock reasonably expected to be purchased under a Put Notice shall not be deemed a Short Sale. The Investor shall, until
such time as the transactions contemplated by this Agreement are publicly disclosed by the Company in accordance with the terms
of this Agreement, maintain the confidentiality of the existence and terms of this transaction and the information included in
the Transaction Documents. The Investor agrees not to disclose any Confidential Information of the Company to any third party,
except for attorneys, accountants, advisors who have a need to know such Confidential Information and are bound by confidentiality,
and shall not use any Confidential Information for any purpose other than in connection with, or in furtherance of, the transactions
contemplated hereby. The Investor acknowledges that the Confidential Information of the Company shall remain the property of the
Company and agrees that it shall take all reasonable measures to protect the secrecy of any Confidential Information disclosed
by the Company.

Article
VI

COVENANTS OF THE COMPANY

Section
6.1               REMOVED
AND RESERVED. 

Section
6.2               LISTING
OF COMMON STOCK. As long as the Investor is the owner of any Put Shares, the Company shall use its commercially reasonable
efforts to continue the listing and trading of the Common Stock on the Principal Market (including, without limitation, maintaining
sufficient net tangible assets) and will comply in all respects with the Company’s reporting, filing and other obligations
under the bylaws or rules of FINRA and the Principal Market. The Company shall not take any action that would reasonably be expected
to result in the delisting or suspension of the Common Stock on the Principal Market. The Company shall promptly, and in no event
later than the following Trading Day, provide to the Investor copies of any notices it receives from any Person regarding the
continued eligibility of the Common Stock for listing on the Principal Market. The Company shall pay all fees and expenses in
connection with satisfying its obligations under this Section 6.2). The Company shall take all action necessary to ensure
that its Common Stock can be transferred electronically as DWAC Shares.

Section
6.3               OTHER
EQUITY LINES. So long as this Agreement remains in effect, the Company covenants and agrees that it will not, without the
prior written consent of the Investor, enter into any other equity line of credit agreement with any other party, without the
Investor’s prior written consent, which consent may be granted or withheld in the Investor’s sole and absolute discretion.

Section
6.4               FILING
OF CURRENT REPORT AND REGISTRATION STATEMENT. The Company agrees that it shall file a Current Report on Form 8-K, including
the Transaction Documents as exhibits thereto, with the SEC within the time required by the Exchange Act, relating to the transactions
contemplated by, and describing the material terms and conditions of, the Transaction Documents (the “Current Report”).
The Company shall permit the Investor to review and comment upon the final pre-filing draft version of the Current Report at least
two (2) Trading Days prior to its filing with the SEC, and the Company shall give reasonable consideration to all such comments.
The Investor shall use its reasonable best efforts to comment upon the final pre-filing draft version of the Current Report within
one (1) Trading Day from the date the Investor receives it from the Company. Pursuant to the terms of the Registration Rights
Agreement, the Company shall also file with the SEC, on or before the 30th (30th) day following the Execution Date, a new registration
statement on Form S-1 (the “Registration Statement”) covering only the resale of the Put Shares and Commitment
Shares.

Section
6.5               ISSUANCE
OF COMMITMENT SHARES. In consideration for the Investor’s execution and delivery of, and performance under this Agreement,
the Company shall cause the Transfer Agent to issue the Commitment Shares to the Investor on the Execution Date. For the avoidance
of doubt, all of the Commitment Shares shall be fully earned as of the Execution Date, and the issuance of the Commitment Shares
is not contingent upon any other event or condition, including, without limitation, the effectiveness of the Registration Statement
or the Company’s submission of a Put Notice to the Investor and irrespective of any termination of this Agreement. The Company
shall register all Commitment Shares with any registration statement filed which registers any Put Shares. 

Section
6.6               DUE
DILIGENCE; CONFIDENTIALITY; NON-PUBLIC INFORMATION. The Investor shall have the right, from time to time as the Investor may
reasonably deem appropriate, to perform reasonable due diligence on the Company during normal business hours. The Company, each
Subsidiary and their respective officers and employees shall provide information and reasonably cooperate with the Investor in
connection with any reasonable request by the Investor related to the Investor’s due diligence of the Company. The Company
confirms that neither it nor any other Person acting on its behalf shall provide the Investor or its agents or counsel with any
information that constitutes or might constitute material, non-public information, unless a simultaneous public announcement thereof
is made by the Company in the manner contemplated by Regulation FD. In the event of a breach of the foregoing covenant by the
Company or any Person acting on its behalf (as determined in the reasonable good faith judgment of the Investor), in addition
to any other remedy provided herein or in the other Transaction Documents, the Investor shall have the right to make a public
disclosure, in the form of a press release, public advertisement or otherwise, of such material, non-public information without
the prior approval by the Company; provided the Investor shall have first provided notice to the Company that it believes it has
received information that constitutes material, non-public information, and the Company shall have had at least twenty-four (24)
hours to publicly disclose such material, non-public information prior to any such disclosure by the Investor, and the Company
shall have failed to publicly disclose such material, non-public information within such time period. The Investor shall not have
any liability to the Company, any Subsidiary, or any of their respective directors, officers, employees, stockholders, affiliates
or agents, for any such disclosure. The Company understands and confirms that the Investor shall be relying on the foregoing covenants
in effecting transactions in securities of the Company.

Section
6.7               PURCHASE
RECORDS. The Company shall maintain records showing the Available Amount at any given time and the date, Investment Amount
and Put Shares for each Option 1 Put or Option 2 Put, contained in the applicable Put Notice.

Section
6.8               TAXES.
The Company shall pay any and all transfer, stamp or similar taxes that may be payable with respect to the issuance and delivery
of any shares of Common Stock to the Investor made under this Agreement.

Section
6.9               USE
OF PROCEEDS. The Company will use the net proceeds from the offering of Put Shares hereunder in the manner described in the
Registration Statement or the SEC Documents.

Section
6.10            OTHER
TRANSACTIONS. The Company shall not enter into, announce or recommend to its stockholders any agreement, plan, arrangement
or transaction in or of which the terms thereof would restrict, materially delay, conflict with or impair the ability or right
of the Company to perform its obligations under the Transaction Documents, including, without limitation, the obligation of the
Company to deliver the Put Shares and the Commitment Shares to the Investor in accordance with the terms of the Transaction Documents.

Section
6.11            INTEGRATION.
In any case subject to the terms of the Registration Rights Agreement, from and after the Execution Date, neither the Company,
nor or any of its Subsidiaries or affiliates will, and the Company shall use its reasonable best efforts to ensure that no Person
acting on their behalf will, directly or indirectly, make any offers or sales of any security or solicit any offers to buy any
security, under circumstances that would require registration of the offer and sale of any of the Securities under the Securities
Act.

Section
6.12            [Intentionally
Omitted.]

Section
6.13            TRANSACTION
DOCUMENTS. On the Execution Date, the Company shall deliver to the Investor executed copies of all of the Transaction Documents.

Article
VII

CONDITIONS TO DELIVERY OF PUT NOTICES AND CONDITIONS TO CLOSING

Section
7.1               CONDITIONS
PRECEDENT TO THE RIGHT OF THE COMPANY TO ISSUE AND SELL PUT SHARES. The right of the Company to issue and sell the Put Shares
to the Investor is subject to the satisfaction of each of the conditions set forth below:

(a)               
ACCURACY OF INVESTOR’S REPRESENTATIONS
AND WARRANTIES. The representations and warranties of the Investor shall be true and correct in all material respects as of
the Execution Date and as of the date of each Closing as though made at each such time.

(b)               
DELIVERY OF DOCUMENTS. The
Investor shall have executed each of the Transaction Documents and delivered the same to the Company.

(c)               
REGISTRATION STATEMENT. The Company shall
not have the right to issue any Put Shares if, as of the date of the Closing for such issuance and sale, the Registration Statement,
and any amendment or supplement thereto, shall fail to be and remain effective for the resale by the Investor of the Put Shares
and Commitment Shares.

Section
7.2               CONDITIONS
PRECEDENT TO THE OBLIGATION OF INVESTOR TO PURCHASE PUT SHARES. The obligation of the Investor hereunder to purchase Put Shares
is subject to the satisfaction of each of the following conditions:

(a)               
REGISTRATION STATEMENT. The Registration
Statement, and any amendment or supplement thereto, shall be and remain effective for the resale by the Investor of the Put Shares
and the Commitment Shares and (i) neither the Company nor the Investor shall have received notice that the SEC has issued or intends
to issue a stop order with respect to such Registration Statement or that the SEC otherwise has suspended or withdrawn the effectiveness
of such Registration Statement, either temporarily or permanently, or intends or has threatened to do so and (ii) no other suspension
of the use of, or withdrawal of the effectiveness of, such Registration Statement or related prospectus shall exist. The Company
shall have prepared and filed with the SEC a final and complete prospectus (the preliminary form of which shall be included in
the Registration Statement) and shall have delivered to the Investor a true and complete copy thereof. Such prospectus shall be
current and available for the resale by the Investor of all of the Securities covered thereby. 

(b)               
ACCURACY OF THE COMPANY’S REPRESENTATIONS
AND WARRANTIES. The representations and warranties of the Company shall be true and correct in all material respects as of
the Execution Date and as of the date of each Closing (except for representations and warranties under the first sentence of Section
4.3, which are specifically made as of the Execution Date and shall be true and correct in all respects as of the Execution
Date).

(c)               
PERFORMANCE BY THE COMPANY. The Company
shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by
this Agreement to be performed, satisfied or complied with by the Company.

(d)               
NO INJUNCTION. No statute, rule, regulation,
executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or adopted by any court or governmental
authority of competent jurisdiction that prohibits or directly and materially adversely affects any of the transactions contemplated
by the Transaction Documents, and no proceeding shall have been commenced that may have the effect of prohibiting or materially
adversely affecting any of the transactions contemplated by the Transaction Documents.

(e)               
ADVERSE CHANGES. Since the date of filing
of the Company’s most recent SEC Document, no event that had or is reasonably likely to have a Material Adverse Effect has
occurred.

(f)                
NO SUSPENSION OF TRADING IN OR DELISTING OF
COMMON STOCK. The trading of the Common Stock shall not have been suspended by the SEC, the Principal Market or FINRA, or
otherwise halted for any reason, and the Common Stock shall have been approved for listing or quotation on and shall not have
been delisted from the Principal Market. In the event of a suspension, delisting, or halting for any reason, of the trading of
the Common Stock, as contemplated by this Section 7.2(f), the Investor shall have the right to return to the Company any
remaining amount of Put Shares associated with such Option 1 Put or Option 2 Put, and the Option 1 Purchase Price or Option 2
Purchase Price (as applicable) with respect to such Option 1 Put or Option 2 Put shall be reduced accordingly.

(g)               
BENEFICIAL OWNERSHIP LIMITATION. As of
the date of the Closing for such issuance and sale, the number of Put Shares to be purchased by the Investor shall not exceed
the number of such shares that, when aggregated with all other shares of Common Stock then owned by the Investor beneficially
or deemed beneficially owned by the Investor, would result in the Investor owning more than the Beneficial Ownership Limitation
(as defined below), as determined in accordance with Section 16 of the Exchange Act and the regulations promulgated thereunder.
For purposes of this Section 7.2(g), in the event that the amount of Common Stock outstanding, as determined in accordance
with Section 16 of the Exchange Act and the regulations promulgated thereunder, is greater on a Closing Date than on the date
upon which the Put Notice associated with such Closing Date is given, the amount of Common Stock outstanding on such Closing Date
shall govern for purposes of determining whether the Investor, when aggregating all purchases of Common Stock made pursuant to
this Agreement, would own more than the Beneficial Ownership Limitation following such Closing Date. The “Beneficial
Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving
effect to the issuance of shares of Common Stock issuable pursuant to a Put Notice.

(h)               
NO KNOWLEDGE. The Company shall have no
knowledge of any event more likely than not to have the effect of causing the Registration Statement to be suspended or otherwise
ineffective (which event is more likely than not to occur within the fifteen (15) Trading Days following the Trading Day on which
such Put Notice is deemed delivered). The Company shall have no knowledge of any untrue statement (or alleged untrue statement)
of a material fact or omission (or alleged omission) of a material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they were made, not misleading, in the Registration Statement, any
effective registration statement filed pursuant to the Registration Rights Agreement or any post-effective amendment or prospectus
which is a part of the foregoing, unless the Company has filed an amendment with the SEC or taken such other.

(i)                
NO VIOLATION OF SHAREHOLDER APPROVAL REQUIREMENT.
The issuance of the Put Shares shall not violate the shareholder approval requirements of the Principal Market.

(j)                
OFFICER’S CERTIFICATE. On the date
of delivery of each Put Notice, the Investor shall have received the Closing Certificate executed by an executive officer of the
Company and to the effect that all the conditions to such Closing shall have been satisfied as of the date of each such certificate.

(k)               
DWAC ELIGIBLE. The Common Stock must be
DWAC Eligible and not subject to a “DTC chill.”

(l)                
SEC DOCUMENTS. All reports, schedules,
registrations, forms, statements, information and other documents required to have been filed by the Company with the SEC pursuant
to the reporting requirements of the Exchange Act (other than Forms 8-K) shall have been filed with the SEC within the applicable
time periods prescribed for such filings under the Exchange Act.

(m)             
TRANSFER AGENT INSTRUCTION LETTER. The
Transfer Agent Instruction Letter shall have been executed and delivered by the Company to the Transfer Agent and acknowledged
and agreed to in writing by the Transfer Agent, and the Company shall have no knowledge of any fact or circumstance that would
prevent the Transfer Agent from complying with the terms of the Transfer Agent Instruction Letter. 

(n)               
NATIONAL SECURITIES EXCHANGE. The Company’s
Common Stock must be listed on a Principal Market.

(o)               
MINIMUM PRICING. The lowest traded price
of the Common Stock in the five (5) Trading Days immediately preceding the respective Put Date must exceed the Floor Price.

(p)               
NO VIOLATION. No statute, regulation,
order, guidance, decree, writ, ruling or injunction shall have been enacted, entered, promulgated, threatened or endorsed by any
federal, state, local or foreign court or governmental authority of competent jurisdiction, including, without limitation, the
SEC, which prohibits the consummation of or which would materially modify or delay any of the transactions contemplated by the
Transaction Documents.

(q)               
LEGAL OPINION. The Company shall cause
to be delivered to the Investor a written opinion of counsel reasonably satisfactory to the Investor, in form and substance reasonably
satisfactory to the Investor and its counsel, relating to the availability and effectiveness of the Registration Statement, as
supplemented by any prospectus supplement or amendment thereto, and regarding the Company’s compliance with the Delaware
Statutes and the federal securities laws of the United States in the issuance, sale and registration of the Put Shares and Commitment
Shares. 

Article
VIII

LEGENDS

Section
8.1               NO
RESTRICTIVE STOCK LEGEND. No restrictive stock legend shall be placed on the share certificates representing the Put Shares.

Section
8.2               INVESTOR’S
COMPLIANCE. Nothing in this Article VIII shall affect in any way the Investor’s obligations hereunder to comply
with all applicable securities laws upon the sale of the Common Stock.

Article
IX

NOTICES; INDEMNIFICATION

Section
9.1               NOTICES.
All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing
and, unless otherwise specified herein, shall be (a) personally served, (b) deposited in the mail, registered or certified, return
receipt requested, postage prepaid, (c) delivered by reputable air courier service with charges prepaid, or (d) transmitted by
hand delivery, telegram, or e-mail as a PDF, addressed as set forth below or to such other address as such party shall have specified
most recently by written notice given in accordance herewith. Any notice or other communication required or permitted to be given
hereunder shall be deemed effective (i) upon hand delivery or delivery by e-mail at the address designated below (if delivered
on a business day during normal business hours where such notice is to be received), or the first business day following such
delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (ii)
on the second business day following the date of mailing by express courier service or on the fifth business day after deposited
in the mail, in each case, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first
occur.

The
addresses for such communications shall be:

If
to the Company:

NuGenerex
Immuno-Oncology Inc.

10102
USA Today Way

Miramar,
FL 33025

Attention:
Joseph Moscato, CEO

E-mail:
jmoscato@nugenerex.com

Phone:
800-391-6755

 

NuGenerex
Immuno-Oncology Inc.

Anthony
S. Crisci, Esq., CPA

Chief
Legal Officer

E-mail:
acrisci@nugenerex.com

 

With
a copy (which shall not constitute notice) to:

 

Carmel,
Milazzo & Feil LLP

55
West 39th Street, 18th Flr

New
York, NY 10018

Attention:
Jeffrey P. Wofford

E-mail:
jwofford@cmfllp.com

 

If
to the Investor:

Oasis
Capital, LLC

208
Ponce de Leon Ave, Suite 1600

San
Juan, PR 00918

E-mail:
adam@oasis-cap.com

Attention:
Adam Long, Managing Partner

 

with
a copy to (that shall not constitute notice)

Nason,
Yeager, Gerson, Harris & Fumero, P.A.

3001
PGA Boulevard, Suite 305

Palm
Beach Gardens, FL 33410

E-mail:
bbernstein@nasonyeager.com

Attention:
Brian Bernstein, Esq.

Either
party hereto may from time to time change its address or e-mail for notices under this Section 9.1 by giving at least ten
(10) days’ prior written notice of such changed address to the other party hereto.

Section
9.2               INDEMNIFICATION.
Each party hereto (an “Indemnifying Party”) agrees to indemnify and hold harmless the other party along with
its officers, directors, employees, and authorized agents and representatives, and each Person or entity, if any, who controls
such party within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act or the rules and regulations
thereunder (an “Indemnified Party”) from and against any and all Damages, joint or several, and any and all
actions in respect thereof to which the Indemnified Party becomes subject to, resulting from, arising out of or relating to (i)
any misrepresentation, breach of warranty or nonfulfillment of or failure to perform any covenant or agreement on the part of
the Indemnifying Party contained in this Agreement, (ii) any untrue statement or alleged untrue statement of a material fact contained
in the Registration Statement, any registration statement pursuant to the Registration Rights Agreement or any post-effective
amendment thereof or supplement thereto, or the omission or alleged omission therefrom of a material fact required to be stated
therein or necessary to make the statements therein not misleading, (iii) any untrue statement or alleged untrue statement of
a material fact contained in any preliminary prospectus or contained in the final prospectus (as amended or supplemented, if the
Company files any amendment thereof or supplement thereto with the SEC) or the omission or alleged omission to state therein any
material fact necessary to make the statements made therein, in the light of the circumstances under which the statements therein
were made, not misleading, or (iv) any violation or alleged violation by the Company of the Securities Act, the Exchange Act,
any state securities law or any rule or regulation under the Securities Act, the Exchange Act or any state securities law, as
such Damages are incurred, except to the extent such Damages result primarily from the Indemnified Party’s failure to perform
any covenant or agreement contained in this Agreement or the Indemnified Party’s negligence, recklessness, fraud, willful
misconduct or bad faith in performing its obligations under this Agreement; provided, however, that the foregoing
indemnity agreement shall not apply to any Damages of an Indemnified Party to the extent, but only to the extent, arising out
of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made by an Indemnifying Party
in reliance upon and in conformity with written information furnished to the Indemnifying Party by the Indemnified Party expressly
for use in the Registration Statement, any post-effective amendment thereof or supplement thereto, or any preliminary prospectus
or final prospectus (as amended or supplemented).

Section
9.3               METHOD
OF ASSERTING INDEMNIFICATION CLAIMS. All claims for indemnification by any Indemnified Party under Section 9.2 shall
be asserted and resolved as follows:

(a)               
In the event any claim or demand in respect of
which an Indemnified Party might seek indemnity under Section 9.2 is asserted against or sought to be collected from such
Indemnified Party by a Person other than a party hereto or an affiliate thereof (a “Third Party Claim”), the
Indemnified Party shall deliver a written notification, enclosing a copy of all papers served, if any, and specifying the nature
of and basis for such Third Party Claim and for the Indemnified Party’s claim for indemnification that is being asserted
under any provision of Section 9.2 against an Indemnifying Party, together with the amount or, if not then reasonably ascertainable,
the estimated amount, determined in good faith, of such Third Party Claim (a “Claim Notice”) with reasonable
promptness to the Indemnifying Party. If the Indemnified Party fails to provide the Claim Notice with reasonable promptness after
the Indemnified Party receives notice of such Third Party Claim, the Indemnifying Party shall not be obligated to indemnify the
Indemnified Party with respect to such Third Party Claim to the extent that the Indemnifying Party’s ability to defend has
been prejudiced by such failure of the Indemnified Party. The Indemnifying Party shall notify the Indemnified Party as soon as
practicable within the period ending thirty (30) calendar days following receipt by the Indemnifying Party of either a Claim Notice
or an Indemnity Notice (as defined below) (the “Dispute Period”) whether the Indemnifying Party disputes its
liability or the amount of its liability to the Indemnified Party under Section 9.2 and whether the Indemnifying Party
desires, at its sole cost and expense, to defend the Indemnified Party against such Third Party Claim.

(i)                
If the Indemnifying Party notifies the Indemnified
Party within the Dispute Period that the Indemnifying Party desires to defend the Indemnified Party with respect to the Third
Party Claim pursuant to this Section 9.3(a), then the Indemnifying Party shall have the right to defend, with counsel reasonably
satisfactory to the Indemnified Party, at the sole cost and expense of the Indemnifying Party, such Third Party Claim by all appropriate
proceedings, which proceedings shall be vigorously and diligently prosecuted by the Indemnifying Party to a final conclusion or
will be settled at the discretion of the Indemnifying Party (but only with the consent of the Indemnified Party in the case of
any settlement that provides for any relief other than the payment of monetary damages or that provides for the payment of monetary
damages as to which the Indemnified Party shall not be indemnified in full pursuant to Section 9.2). The Indemnifying Party
shall have full control of such defense and proceedings, including any compromise or settlement thereof; provided, however,
that the Indemnified Party may, at the sole cost and expense of the Indemnified Party, at any time prior to the Indemnifying Party’s
delivery of the notice referred to in the first sentence of this clause (i), file any motion, answer or other pleadings or take
any other action that the Indemnified Party reasonably believes to be necessary or appropriate to protect its interests; and provided,
further, that if requested by the Indemnifying Party, the Indemnified Party will, at the sole cost and expense of the Indemnifying
Party, provide reasonable cooperation to the Indemnifying Party in contesting any Third Party Claim that the Indemnifying Party
elects to contest. The Indemnified Party may participate in, but not control, any defense or settlement of any Third Party Claim
controlled by the Indemnifying Party pursuant to this clause (i), and except as provided in the preceding sentence, the Indemnified
Party shall bear its own costs and expenses with respect to such participation. Notwithstanding the foregoing, the Indemnified
Party may takeover the control of the defense or settlement of a Third Party Claim at any time if it irrevocably waives its right
to indemnity under Section 9.2 with respect to such Third Party Claim.

(ii)              
If the Indemnifying Party fails to notify the
Indemnified Party within the Dispute Period that the Indemnifying Party desires to defend the Third Party Claim pursuant to this
Section 9.3(a), or if the Indemnifying Party gives such notice but fails to prosecute vigorously and diligently or settle
the Third Party Claim, or if the Indemnifying Party fails to give any notice whatsoever within the Dispute Period, then the Indemnified
Party shall have the right to defend, at the sole cost and expense of the Indemnifying Party, the Third Party Claim by all appropriate
proceedings, which proceedings shall be prosecuted by the Indemnified Party in a reasonable manner and in good faith or will be
settled at the discretion of the Indemnified Party(with the consent of the Indemnifying Party, which consent will not be unreasonably
withheld). The Indemnified Party will have full control of such defense and proceedings, including any compromise or settlement
thereof; provided, however, that if requested by the Indemnified Party, the Indemnifying Party will, at the sole cost and expense
of the Indemnifying Party, provide reasonable cooperation to the Indemnified Party and its counsel in contesting any Third Party
Claim which the Indemnified Party is contesting. Notwithstanding the foregoing provisions of this clause (ii), if the Indemnifying
Party has notified the Indemnified Party within the Dispute Period that the Indemnifying Party disputes its liability or the amount
of its liability hereunder to the Indemnified Party with respect to such Third Party Claim and if such dispute is resolved in
favor of the Indemnifying Party in the manner provided in clause (iii) below, the Indemnifying Party will not be required to bear
the costs and expenses of the Indemnified Party’s defense pursuant to this clause (ii) or of the Indemnifying Party’s
participation therein at the Indemnified Party’s request, and the Indemnified Party shall reimburse the Indemnifying Party
in full for all reasonable costs and expenses incurred by the Indemnifying Party in connection with such litigation. The Indemnifying
Party may participate in, but not control, any defense or settlement controlled by the Indemnified Party pursuant to this clause
(ii), and the Indemnifying Party shall bear its own costs and expenses with respect to such participation.

(iii)            
If the Indemnifying Party notifies the Indemnified
Party that it does not dispute its liability or the amount of its liability to the Indemnified Party with respect to the Third
Party Claim under Section 9.2 or fails to notify the Indemnified Party within the Dispute Period whether the Indemnifying
Party disputes its liability or the amount of its liability to the Indemnified Party with respect to such Third Party Claim, the
amount of Damages specified in the Claim Notice shall be conclusively deemed a liability of the Indemnifying Party under Section
9.2 and the Indemnifying Party shall pay the amount of such Damages to the Indemnified Party on demand. If the Indemnifying
Party has timely disputed its liability or the amount of its liability with respect to such Third Party Claim, the Indemnifying
Party and the Indemnified Party shall proceed in good faith to negotiate a resolution of such dispute; provided, however,
that if the dispute is not resolved within thirty (30) days after the Claim Notice, the Indemnifying Party shall be entitled to
institute such legal action as it deems appropriate.

(b)               
In the event any Indemnified Party should have
a claim under Section 9.2 against the Indemnifying Party that does not involve a Third Party Claim, the Indemnified Party
shall deliver a written notification of a claim for indemnity under Section 9.2 specifying the nature of and basis for
such claim, together with the amount or, if not then reasonably ascertainable, the estimated amount, determined in good faith,
of such claim (an “Indemnity Notice”) with reasonable promptness to the Indemnifying Party. The failure by
any Indemnified Party to give the Indemnity Notice shall not impair such party’s rights hereunder except to the extent that
the Indemnifying Party demonstrates that it has been irreparably prejudiced thereby. If the Indemnifying Party notifies the Indemnified
Party that it does not dispute the claim or the amount of the claim described in such Indemnity Notice or fails to notify the
Indemnified Party within the Dispute Period whether the Indemnifying Party disputes the claim or the amount of the claim described
in such Indemnity Notice, the amount of Damages specified in the Indemnity Notice will be conclusively deemed a liability of the
Indemnifying Party under Section 9.2 and the Indemnifying Party shall pay the amount of such Damages to the Indemnified
Party on demand. If the Indemnifying Party has timely disputed its liability or the amount of its liability with respect to such
claim, the Indemnifying Party and the Indemnified Party shall proceed in good faith to negotiate a resolution of such dispute;
provided, however, that if the dispute is not resolved within thirty (30) days after the Claim Notice, the Indemnifying Party
shall be entitled to institute such legal action as it deems appropriate.

(c)               
The Indemnifying Party agrees to pay the Indemnified
Party, promptly as such expenses are incurred and are due and payable, for any reasonable legal fees or other reasonable expenses
incurred by them in connection with investigating or defending any such Claim.

(d)               
The indemnity provisions contained herein shall
be in addition to (i) any cause of action or similar rights of the Indemnified Party against the Indemnifying Party or others,
and (ii) any liabilities the Indemnifying Party may be subject to.

Article
X

MISCELLANEOUS

Section
10.1            GOVERNING
LAW. This Agreement shall be governed by and interpreted in accordance with the laws of the State of New York without regard
to the principles of conflicts of law (whether of the State of New York or any other jurisdiction). 

Section
10.2            ARBITRATION.
Any disputes, claims, or controversies arising out of or relating to the Transaction Documents, or the transactions, contemplated
thereby, or the breach, termination, enforcement, interpretation or validity thereof, including the determination of the scope
or applicability of this Agreement to arbitrate, shall be referred to and resolved solely and exclusively by binding arbitration
to be conducted before the Judicial Arbitration and Mediation Service (“JAMS” ), or its successor pursuant
the expedited procedures set forth in the JAMS Comprehensive Arbitration Rules and Procedures (the “Rules”
), including Rules 16.1 and 16.2 of those Rules. The arbitration shall be held in New York, New York, before a tribunal consisting
of three (3) arbitrators each of whom will be selected in accordance with the “strike and rank” methodology set forth
in Rule 15. Either party to this Agreement may, without waiving any remedy under this Agreement, seek from any federal or state
court sitting in the State of New York any interim or provisional relief that is necessary to protect the rights or property of
that party, pending the establishment of the arbitral tribunal. The costs and expenses of such arbitration shall be paid by and
be the sole responsibility of the Company, including but not limited to the Investor’s attorneys’ fees and each arbitrator’s
fees. The arbitrators’ decision must set forth a reasoned basis for any award of damages or finding of liability. The arbitrators’
decision and award will be made and delivered as soon as reasonably possibly and in any case within sixty (60) days’ following
the conclusion of the arbitration hearing and shall be final and binding on the parties and may be entered by any court having
jurisdiction thereof.

Section
10.3            JURY
TRIAL WAIVER. THE COMPANY AND THE INVESTOR HEREBY WAIVE A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT
BY EITHER OF THE PARTIES HERETO AGAINST THE OTHER IN RESPECT OF ANY MATTER ARISING OUT OF OR IN CONNECTION WITH THE TRANSACTION
DOCUMENTS.

Section
10.4            ASSIGNMENT.
This Agreement shall be binding upon and inure to the benefit of the Company and the Investor and their respective successors.
Neither this Agreement nor any rights of the Investor or the Company hereunder may be assigned by either party to any other Person.

Section
10.5            NO
THIRD PARTY BENEFICIARIES. This Agreement is intended for the benefit of the Company and the Investor and their respective
successors, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as set forth
in Article IX.

Section
10.6            TERMINATION.
At any time after the effectiveness of the Registration Statement, the Company shall have the
option to terminate this Agreement for any reason or for no reason by delivering written notice (a “Company Termination
Notice”) to the Investor electing to terminate this Agreement without any liability whatsoever of any party to any other
party under this Agreement (except as set forth below). The Company Termination Notice shall not be effective until one business
day after it has been received by the Investor, provided that this Agreement cannot be terminated (i) while the Investor holds
any Put Shares and (ii) prior to the expiration of the Registration Period (as defined in the Registration Rights Agreement).
In addition, this Agreement shall automatically terminate on the earlier of (i) the end of the Commitment Period; (ii)
the date that the Company sells and the Investor purchases the Maximum Commitment Amount; or (iii) the date in which the Registration
Statement is no longer effective, or (iv) the date that, pursuant to or within the meaning of any Bankruptcy Law, the Company
commences a voluntary case or any Person commences a proceeding against the Company, a Custodian is appointed for the Company
or for all or substantially all of its property or the Company makes a general assignment for the benefit of its creditors. Notwithstanding
the foregoing, in the event of termination of this Agreement, the provisions of Articles III, IV, V, VI, IX and the agreements
and covenants of the Company and the Investor set forth in this Article X shall survive the termination of this Agreement
for the maximum length of time allowed under applicable law.

Section
10.7            ENTIRE
AGREEMENT. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of
the Company and the Investor with respect to the matters covered herein and therein and supersede all prior agreements and understandings,
oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and
schedules.

Section
10.8            FEES
AND EXPENSES. Except as expressly set forth in the Transaction Documents or any other writing to the contrary, each party
shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred
by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall
pay all Transfer Agent fees, stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to
the Investor. The Company shall pay $25,000  to the Investor on the Execution Date
for reimbursement of the Investor’s transaction fees relating to the preparation of the Transaction Documents. 

Section
10.9            COUNTERPARTS.
This Agreement may be executed in multiple counterparts, each of which may be executed by less than all of the parties and shall
be deemed to be an original instrument which shall be enforceable against the parties actually executing such counterparts and
all of which together shall constitute one and the same instrument. This Agreement may be delivered to the other parties hereto
by e-mail of a copy of this Agreement bearing the signature of the parties so delivering this Agreement.

Section
10.10        SEVERABILITY.
In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable
or void, this Agreement shall continue in full force and effect without said provision; provided that such severability shall
be ineffective if it materially changes the economic benefit of this Agreement to any party.

Section
10.11        FURTHER
ASSURANCES. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.

Section
10.12        NO
STRICT CONSTRUCTION. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.

Section
10.13        EQUITABLE
RELIEF. Each party acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the other
by vitiating the intent and purpose of the transaction contemplated hereby. Accordingly, each party acknowledges that the remedy
at law for a breach of its obligations under this Agreement will be inadequate and agrees, in the event of a breach or threatened
breach by the such party of the provisions of this Agreement, that the other party shall be entitled, in addition to all other
available remedies at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining,
preventing or curing any breach of this Agreement and to enforce specifically the terms and provisions hereof, without the necessity
of showing economic loss and without any bond or other security being required.

Section
10.14        TITLE
AND SUBTITLES. The titles and subtitles used in this Agreement are used for the convenience of reference and are not to be
considered in construing or interpreting this Agreement.

Section
10.15        AMENDMENTS;
WAIVERS. No provision of this Agreement may be amended or waived by the parties from and after the date that is one (1) Trading
Day immediately preceding the initial filing of the Registration Statement with the SEC. Subject to the immediately preceding
sentence, (i) no provision of this Agreement may be amended other than by a written instrument signed by both parties hereto and
(ii) no provision of this Agreement may be waived other than in a written instrument signed by the party against whom enforcement
of such waiver is sought. No failure or delay in the exercise of any power, right or privilege hereunder shall operate as a waiver
thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof
or of any other right, power or privilege.

Section
10.16        PUBLICITY.
The Company and the Investor shall consult with each other in issuing any press releases or otherwise making public statements
with respect to the transactions contemplated hereby and no party shall issue any such press release or otherwise make any such
public statement, other than as required by law, without the prior written consent of the other parties, which consent shall not
be unreasonably withheld or delayed, except that no prior consent shall be required if such disclosure is required by law, in
which such case the disclosing party shall provide the other party with prior notice of such public statement. Notwithstanding
the foregoing, the Company shall not publicly disclose the name of the Investor without the prior written consent of the Investor,
except to the extent required by law. The Investor acknowledges that this Agreement and all or part of the Transaction Documents
may be deemed to be “material contracts,” as that term is defined by Item 601(b)(10) of Regulation S-K, and that the
Company may therefore be required to file such documents as exhibits to reports or registration statements filed under the Securities
Act or the Exchange Act. The Investor further agrees that the status of such documents and materials as material contracts shall
be determined solely by the Company, in consultation with its counsel.

 

 

**
Signature Page Follows **

 

    	 	1	 

     

    

 

IN
WITNESS WHEREOF, the parties have caused this Agreement to be duly executed by their respective officers thereunto duly authorized
as of the Execution Date.

	 	NUGENEREX IMMUNO-ONCOLOGY INC.
	 	 
	 	By: /s/Joseph Moscato
	 	Name: Joseph Moscato
	 	Title: CEO
	 	 
	 	 
	 	OASIS CAPITAL, LLC
	 	 
	 	By: /s/Adam Long
	 	Name: Adam Long
	 	Title: Managing Partner

 

 

**
Signature Page to Equity Purchase Agreement **

 

    	 	2	 

     

    

EXHIBIT
A

FORM
OF PUT NOTICE

TO:
OASIS CAPITAL, LLC

 

DATE:

We
refer to the Equity Purchase Agreement, dated July _______, 2020 (the “Agreement”), entered into by and between
NuGenerex Immuno-Oncology Inc. and you. Capitalized terms defined in the Agreement shall, unless otherwise defined herein, have
the same meaning when used herein.

We
hereby:

1)Give
you notice that we require you to purchase  Put Shares pursuant to an [ ] Option 1 Put or [ ] Option 2 Put; and

2)
Certify that, as of the date hereof, the conditions set forth in Section 7.2 of the Agreement are
satisfied.

NUGENEREX
IMMUNO-ONCOLOGY INC.

By:

Name:
       

Title:
       

    	 	3	 

     

    

EXHIBIT
B

FORM
OF OFFICER’S CERTIFICATE

OF
NUGENEREX IMMUNO-ONCOLOGY INC.

Pursuant
to Section 7.2(j) of that certain equity purchase agreement, dated July ___, 2020 (the “Agreement”),
by and between NuGenerex Immuno-Oncology Inc. (the “Company”) and Oasis Capital, LLC (the “Investor”),
the undersigned, in his capacity as Chief Financial Officer of the Company, and not in his individual capacity, hereby certifies,
as of the date hereof (such date, the “Condition Satisfaction Date”), the following:

1.       The
representations and warranties of the Company contained in the Agreement are true and correct in all material respects as of the
Condition Satisfaction Date as though made on the Condition Satisfaction Date (except for representations and warranties specifically
made as of a particular date) with respect to all periods, and as to all events and circumstances occurring or existing to and
including the Condition Satisfaction Date, except for any conditions which have temporarily caused any representations or warranties
of the Company set forth in the Agreement to be incorrect and which have been corrected with no continuing impairment to the Company
or the Investor; and

2.       All
of the conditions precedent to the obligation of the Investor to purchase Put Shares set forth in the Agreement, including but
not limited to Section 7.2 of the Agreement, have been satisfied as of the Condition Satisfaction Date.

Capitalized
terms used herein shall have the meanings set forth in the Agreement unless otherwise defined herein.

IN
WITNESS WHEREOF, the undersigned has hereunto affixed his hand as of _________ ___, 2020.

 

By:

Name:

Title:

    	 	4	 

     

    

EXHIBIT
C

FORM
OF TRANSFER AGENT

INSTRUCTION
LETTER

 

 

 

 

 

 

    	 	5	 

     

    

EXHIBIT
D

FORM
OF REGISTRATION RIGHTS AGREEMENT

 

 

 

 

    	 	6	 

     

    

DISCLOSURE
SCHEDULES

 

Schedule
4.10 Registration Rights.

Registration
rights are described in the following SEC Documents:

 

Schedule
4.4 Listing and Maintenance Requirements.

(a) Notices of Non-Compliance

(b) Continued
Compliance

    	 	7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]